key: cord-0033437-9ds2t03o
authors: nan
title: Oral Presentations_Tuesday
date: 2009-08-08
journal: Eur J Nucl Med Mol Imaging
DOI: 10.1007/s00259-009-1236-4
sha: 2dcb19abc43defd823956eae997288f411a6e6a5
doc_id: 33437
cord_uid: 9ds2t03o

nan

Defining volumes of interest (VOI) within the human brain is a prerequisite for many types of analysis. These include morphometric measurements as well as statistically describing the signal inside the VOI, be it within the image used for defining the VOI itself (usually structural MRI) or in an image which is in register (e.g. PET, SPECT, fMRI). Similarly VOIs can be used to define seed points for DTI measures. The gold standard for defining VOIs remains manual delineation by an expert. However, training of experts and manual delineation itself are time consuming, repetitive, and not scalable for modern image repositories which can contain hundreds or thousands of scans. An alternative to manual delineations are automatic VOI definitions. Since the early 1980s, single subject labelled datasets ("atlases") have been registered with unseen images for this purpose. Such methods are intrinsically limited by intersubject neuroanatomical differences: a single atlas never captures the variability in unseen datasets. Registration via intermediate datasets improves the accuracy of single-subject methods (Collins DL et al. 1999) but is inferior to using single atlases concatenating information from multiple subjects (the "maximum probability map" approach, Hammers A, Allom R et al., 2003) . Both approaches are vastly outperformed by individually registering multiple atlases to an unseen target and choosing the atlas label with the highest probability in target space (Rohlfing T et al. 2004 , Heckemann RA et al. 2006 . Large data bases containing multiple atlases with multiple regions are now becoming available (e.g. Heckemann RA et al. 2006 , Gousias IS et al. 2008 , Shattuck DW et al. 2008 .

Differences in the quality of the underlying manual segmentations influence the quality of automatic segmentations (e.g. Klein A et al. 2005) . The type of registration between the structural scans underlying the atlases plays a major role for segmentation outcome. While there is no point-to-point correspondence between brains, registration methods using non-rigid mapping and large numbers of degrees of freedom outperform simpler methods (reviewed by Klein A et al. 2009 ). Multi-atlas methods have been successfully used for screening for pathology (Hammers A et al. 2007 ) and decision support in radiology (Heckemann RA et al. 2008 ). Finally, it is possible to "fine-tune" segmentation methods to perform particularly well for a given structure. Such methods can perform better than multi-atlas registration methods (e.g. Chupin M et al. 2009 , van der Lijn F et al. 2008 but have yet to be extended to whole-brain anatomical segmentations.

Ictal SPECT in the presurgical evaluation of refractory partial epilepsy W. Van Paesschen; UZ Leuven, Leuven, BELGIUM.

Epilepsy is a common chronic neurological disorder that is controlled with medication in around 70% of cases. When partial seizures are recurrent despite anti-epileptic drugs, resection of the epileptogenic cortex may be considered. Single photon emission computed tomography (SPECT) is used to determine the seizure onset zone, which needs to be resected in order to render a patient seizure free. Correct localization of the ictal onset zone using SPECT is associated with a better surgical outcome. Ictal perfusion SPECT imaging using 99m Tc-ethyl cysteinate dimer (ECD) or 99m Tc-hexamethylpropyleneamine oxime (HMPAO) is able to detect the seizure onset zone in a majority of cases, especially in patients with temporal lobe epilepsy. Interictal SPECT imaging, which is more widely available, is unreliable to determine the ictal onset zone and is usually only used for comparison with ictal SPECT images. Assessment of the ictal onset zone using subtracted ictal and interictal studies, overlayed on structural imaging (SISCOM) has proven to be more sensitive and more specific compared to visual assessment. Video-electroencephalography (EEG) monitoring in combination with ictal SPECT imaging, however, is only available in specialized centers. It is important to inject the perfusion tracer as early as possible after the beginning of a seizure and to be aware of patterns of seizure propagation. Propagation patterns typically present as hyperperfusion clusters connected through small trails of hyperperfusion, giving an hour-glass appearance. The largest hyperperfusion cluster with the highest z-score often represents ictal propagation. Full resection of the SISCOM hyperperfusion cluster is usually not required to render a patient seizure free. In conclusion, ictal SPECT is a highly accurate imaging technique in defining brain regions involved in ictal activity. Due to the poor time-resolution of SPECT versus the electrophysiological changes in seizures, ictal SPECT often shows both the ictal onset zone and seizure propagation pathways. A correct interpretation of the ictal SPECT images, therefore, requires knowledge of the results of the full presurgical evaluation. The logistics of ictal SPECT are elaborate and require optimal collaboration between neurologists and nuclear medicine physicians, and explain why ictal SPECT is used in a limited number of centres.

substituting for hydrogen, can be incorporated into a wide variety of substrates or substrate analogs that participate in diverse metabolic pathways without altering the biochemical properties of the substrate of interest. These ligands enable the assessment of different metabolic processes including free fatty acid metabolism ( 11 C-palmitate and 11 C-acetate), oxygen metabolism ( 15 O 2 and 11 C-acetate) and glucose utilization ( 18 F-fluorodeoxyglucose and 11 Cglucose). The short physical half-life of the positron emitting radionuclides facilitates the performance of sequential studies with a favorable radiation exposure to the subject when compared with conventional single photon radionuclides. Accordingly, some of these tracers have been used in combination to probe more than one metabolic pathway simultaneously. The similarity of positron emitters with their non radioactive equivalents means that the labelled products are chemically and biochemically almost identical to the original compounds and therefore the information gained using the radiolabelled compounds reflects accurately that of the original non labelled molecules. By combining the knowledge of the metabolic pathways of interest with kinetic models that carefully describe the fate of the tracer in myocardial tissue and blood, an accurate interpretation of the tracer kinetics as they relate to the metabolic process of interest can be achieved. Exploiting the PET detection scheme which permits accurate quantification of activity in the field of view with appropriate kinetic models it is therefore possible to quantify the metabolic parameters (e.g. μmol/g/min). Most of these tracers have been used for pathophysiological studies and only 18 F-fluorodeoxyglucose is used routinely in clinical practice for studying myocardial viability. Appropriate diagnosis and therapy of coronary artery disease (CAD) frequently require information about both the morphological and functional status of the coronary artery tree. Thus, combined imaging consisting of invasive coronary angiography (ICA) plus myocardial perfusion imaging (MPI) is practiced in clinical routine diagnostic of patients with stable angina since many years and can therefore be accepted as the reference standard in the diagnosis of hemodynamically relevant coronary artery stenoses. Both morphological and functional information are mandatory for the decision of performing an interventional therapy or initiating/maintaining medical treatment in numerous symptomatic patients. The hemodynamically relevance of coronary artery lesions is a major condition to decide whether an interventional therapy should be performed or not. A non-invasive concept providing both information could provide accurate allocation of perfusion defects to their determining coronary lesion and specific morphological and functional classification of patients with coronary artery disease. Myocardial perfusion PET with 13 N-ammonia or 82 Rb has shown high sensitivity and specificity in the detection of coronary artery stenoses and has shown superior compared to SPECT due to a higher accuracy and the opportunity to provide absolute quantification data. In addition, PET/CT scanners are widely available, attributable primarily to the technology's widely accepted role in clinical oncology, so that CT attenuation correction and calcium scoring can simply be performed. There are also initial data, showing the feasibility of combined PET/CT angiography as an alternative non-invasive concept in clinical decision making and therapy planning of coronary artery disease. Additionally, the implementation of coronary calcium scoring to 82 Rb perfusion PET has shown incremental prognostic value as compared to perfusion PET regional brain distribution of [11C]PEO was investigated in vivo with PET and in ex vivo studies. Results: PEO binds with high affinity binding to κ-OR (Ki=0.12±0.08 nM) and μ-OR (Ki= 0.18±0.06 nM), and with moderate affinity to δ-OR (Ki=5.1±0.6 nM). PEO has 105 and 113 % of the potency of the full agonists DAMGO (μ-OR) and U69593 (κ-OR), respectively. The initial uptake of [11C] PEO in the brain of rats was high, ranging from 0.82±0.02% in the frontal cortex to 0.67±0.03 % in the cerebellum at 5 min after injection. The ratio of radioactivity in striatum, thalamus and frontal cortex to that in the cerebellum, which can be used as a measure of specific binding, was in the range 2.95±0.18-3.78±0.22 and 4.47±0.23-5.23±0.27 at 20 and 60 min p.i., respectively. When rats were treated with the μ-antagonist Cyprodime (2 mg/kg, i.v.) 10 min before the injection of [11C]PEO and sacrificed 20 min after, specific binding of the radioligand in the striatum, thalamus and frontal cortex was reduced by 86, 84 and 82% compared to the control group. On the other hand, when the rats were treated with Salvinorine A, a κ-OR selective agonist at a dose of 2 mg/kg, the binding of the [11C]PEO in striatum, thalamus and frontal cortex was reduced by only 5, 7 and 11 %, respectively. Micro-PET imaging experiments in vivo in rats confirmed the rapid brain entry of [11C]PEO as well as its uptake in brain regions containing a high concentration of the μ-OR. Conclusions: We have provided a 11C-labelled orvinol which has a saturable and μ-OR selective binding in rat brain. A study on the sensitivity of 11C-PEO for detecting changes to the availability of μ-OR is in progress.

with RP-HPLC. The log P and biodistribution in mice at 2 and 60 min p.i of [ 11 C]-1 were studied.

Calcium imaging experiments, using fura-2 as dye, were performed with HEK293 cells expressing hTRPV1 to determine the IC 50 of 1. Results. 1 was shown to act as an antagonist of hTRPV1. Ca 2+ responses to 100 nM capsaicine were inhibited in a concentration-dependent manner, with an IC 50 of ± 180 nM. The log P octanol/buffer value of [ 11 C]-1 was 1.82, suggesting that it may cross the BBB. After intravenous injection in mice, brain uptake was high (2.3% ID at 2 min p.i.) and washout was rapid (0.2% ID at 60 min p.i.). [ 11 C]-1 was also efficiently cleared from plasma (2 min: 4.7% ID; 60 min: 0.5% ID), mainly by the hepatobiliary pathway. Conclusion. N-(3hydroxyphenyl)-4-chlorocinnamide (2) was synthesized and efficiently labeled with carbon-11 to obtain compound [ 11 C]-1, which has favourable biodistribution characteristics in normal mice.

Work is in progress to further evaluate the biological properties of [ 11 C]-1. A µPET study in rats and metabolite study are in progress. ]-fludarabine was efficiently synthesized (60% yield decay corrected, radiochemical purity>99%). In animals studies, data revealed at 60min post injection -in controls a relatively high uptake in lymphoid organs such as the spleen (9.2%±0.03ID/g), -in SCID mice this uptake is strongly reduced (2.2%±0.3ID/g) -in xenografted SCID mice a maximum tumor uptake is reached after 20min with an higher degree in tumor (6.6%±0.6ID/g) versus others organs at 60min. Conclusion An efficient method for the radiosynthesis of [ 18 F]-fludarabine was developed.

The preliminary biological evaluation as a new PET tracer for lymphoma is very promising.

1304 -Tuesday, October 13, 2009, 11:30 -13:00, Hall 117

Technologists Oral Session 3

Introduction Bone Scintigraphy is a noninvasive and very sensitive Nuclear Medicine diagnostic method in detecting early bone lesions. Between the important technical details to consider when dealing with patient preparation there is the hydration level. The aim of this study is focused on assessing the value of hydration on clinical image quality of bone scans. Material and Methods Fifty five patients (30 females and 25 males, aged between 30 to 80 years old, with an average age of 61,6 years) with indication to perform bone scintigraphy were imaged and previously divided into three groups according to the level and moment of hydration: group 1 (3 females and 3 males) with insufficient hydration (below 500 mL); group 2 (15 females and 12 males) with hydration (21 mL/kg) after radiopharmaceutical administration; group 3 (12 females and 10 males) with hydration (7 mL/kg; 45 minutes) before and after (21 mL/kg) radiopharmaceutical administration. Each patient received 740 to 925 MBq of 99mTc-HDP and whole body images were acquired 2.5 to 3 hours after using standardized acquisition parameters.

Regions of interest (ROI) were drawn in the diaphysis of the left femur, on soft tissue of the right lower limb and externally to the right knee (background ROI). Bone/soft tissue ratio, bone/background ratio and soft tissue/background ratios were calculated. Statistical analysis was performed using a test of hypotheses for the difference between means in independent samples and the chi-square test to investigate in each group, the relation/dependence of bone/soft tissue ratio and the gender of patients. Results There are statistical significant differences between the three groups of patients concerning the average bone/soft tissue ratio in three groups (u1 = 2.8859; u2 = 3.3864; u3 = 3.4264). Concerning chi-square test we found that bone/soft tissue ratios are independent of the gender (X2 (df) of 0.5985). Conclusion Based on these results it is possible to conclude that bone/soft tissue ratio in fact increases with the level of hydration and so the related image quality. Furthermore, we found that starting hydration even before radiopharmaceutical administration can help to improve image contrast and image quality. Aim: Patient dose for F18-FDG is mostly administered calculated as a standard dose per kg patient weight. Modern PET-scanners are introduced with terms as 'half dose imaging' or 'half time imaging'. However, the NECR curves of a PET-scanner show where the scanner is functioning optimal. Aim is to objectively calculate the patient dose to be administered based on the NECR of the PET scanner. Methods: NECR curves and values of the PET-scanner (Siemens Biograph 40 TrueV) were measured according to the NEMA NU-2 2007 protocol. F18-FDG patient studies were acquired with a standard patient dose of 3,5 MBq / kg with a standard protocol of 4 min / bed position. Totals and delayed randoms counts were recorded in separate sinograms. For each patient and bed position, with exception of the head region, an individual NECR curve is calculated similar to [1] . Patient length, weight, body mass index (BMI) and dose were registered The dose which should give optimal response was determined retrospectively. Correlations between the proposed optimal dose and given patient parameters were calculated. Results: Different to [1] is the use of a new generation PET-scanner. Also we found out that the individual patient scatter fraction is not relevant due to normalisation of the NECR curve. Further we used the individual totals sinogram to create the masks. The NECR of this PET scanner is much higher than the one used in [1] . Images were reported of good clinical quality. The individual patient NECR was found to be at 66% of maximal NECR. Injected dose was accordingly at 33% of dose at maximum NECR. We found a higher correlation of calculated dose with weight than with BMI. Conclusions: The methodology developed allows estimating injected dose by patient weight, adapted to the NECR curve of the scanner. This estimated injected dose is at 66% of the maximum NECR of the scanner. Dose reduction results in operating at lower percentages of the maximum NECR. Image quality phantom studies are necessary to determine the achievability of this dose reduction. References: Aim Myocardial perfusion PET-CT with Rb-82 is a promising diagnostic tool newly available in Europe. Our aim was to estimate radiation dose to staff involved in rest-stress myocardial perfusion studies with Rb-82 PET-CT in our center. Materials & methods We considered 4 different "worker" categories (physician, technologist, nurse and "quality controller"). The physician controls the infusion device that delivers the eluted activity, being present in the PET room during stress and rest acquisition. The nurse prepares the patient for ECG and arterial pressure monitoring, and is present in the PET room during stress and rest acquisition. Both the physician and the nurse stood >2-3m away from the patient during and shortly after the Rb-82 infusion, when possible. The technologist installs the patient on the PET-CT, and controls the acquisition from an adjacent room. Additionally, a quality controller verifies the conformity of the eluate once a day, performing 3 to 4 blank elutions before allowing the system to be used in patients. Each staff member had a personal digital torso dosimeter. Measurements were discarded as soon as FDG was present in the PET unit or a staff member had to leave the controlled area during the procedure. Results Staff exposure was measured during clinical examinations of 32 patients. All patients received the same activity for stress and rest (1600 MBq). Measured doses per elution for each "worker" category are presented in following Conclusion The radiation dose remains small, even for the physician standing in the injection room during Rb-82 infusion. The physician dose for a stress-rest study is similar to those obtained by other groups for Tc-99m-MIBI stress-rest scintigraphy. Doses to physician and nurse might be further reduced using a shield or stressing the importance of increasing the distance from injection device and patient after injection. As expected, doses to technologists who stay in the shielded control room are very low.

extra-cardiac activity that interfered with image quality and interpretation. Results: The most common effects were facial flushing, abdominal/ throat pressure and discomfort in the arms. Diagnosis is a multidisciplinary approach and requests detailed registration of sleep patterns that include a polysomnogram. There are several treatment options with variable efficacy. Aim: to investigate changes in regional brain glucose metabolism during episodes of central sleep apnea and compare them with baseline. Material and methods: setting-up for these studies is highly demanding because it requests a group effort well timed. Patients arrive to the polysomnogram room where they are prepared for registration (electrodes placed on the scalp, lying flat on a bed, significantly reduced light and noise). Two people are always nearby, the polysomnogram technician and a nuclear medicine technician with the FDG dose prepared for intravenous administration. FDG has to be administered during the episode of central sleep apnea registered on the polysomnogram -only a few seconds duration. PET imaging is performed at 30 minutes and 3 hours post-injection during central sleep apnea episode. The same protocol is followed at baseline. Qualitative image evaluation by an experience nuclear medicine physician is complemented by quantitative analysis using a home-made registration protocol. Results: so far, we were successful in obtaining central sleep apnea data in three subjects for comparison with baseline. The overall evaluation reveals that FDG uptake is generally higher after central sleep apnea episode than at baseline. This is observed in the cortical and subcortical gray-matter structures. In one of the individuals there was regional differences, mainly in the brainstem and thalamus. Conclusion: we demonstrate that investigation of brain glucose metabolism during central sleep apnea episodes is feasible by implementing a team work effort that includes polysomnographic registration of sleep patterns. Overall glucose metabolism is stimulated during central sleep apnea. Regional differences (brainstem and thalamus) deserve further investigation and are ongoing.

Comparison of methods for uptake calculation in lymphatic mapping using SPECT/CT A. Bartel, T. Wendler, J. Grahneis, K. Herrmann, A. K. Buck; Technische Universität München, Muenchen, GERMANY.

Aim: Quantify the difference in the uptake of sentinel lymph nodes using different calculation procedures available with SPECT/CT. Methods: A series of 40 breast cancer patients undergoing indicated lymphatic mapping was examined with planar scintigraphy and SPECT/CT. The uptake of the sentinel nodes was determined from the attenuation corrected SPECT images using two methods: In a first approach all coronal slices were added and a 2D ROI was drawn around the sentinel nodes. In a second approach the uptake was calculated defining 3D ROIs in an ad hoc volumetric analysis tool. The uptake was calculated as the amount of counts in the ROI divided by the counts of the complete image. Results: At least 1 sentinel node was seen in 37 of the 40 patients. In the 3D visualization a total of 68 nodes could be mapped, whereas in the 2D one only 53 nodes were mapped. In 5 patients the 2D visualization did not allow to discriminate nodes in a conglomerate (11 nodes). In 3 patients it was impossible to separate conglomerates in 3D (5 nodes). The uptake in 3D was in average 82,8% lower (std. dev. 172%) than the one calculated using the 2D method. In all but in 3 cases the 2D uptake was always higher than the 3D uptake.

Overflow was not present in any calculation using the 3D method, while it was reported in all 2D sumation images. In a few cases the SPECT images were reconstructed in a thinner matrix eliminating the overflow in the 2D sumation images. However, reconstruction in matrices with higher resolution involved reconstruction time approximately 16x or 64x longer (depending if resolution was increased by 2 or 4 times). The time to calculate the uptake in 2D was 60% shorter in average than the time needed to determine it in 3D. Conclusions: The calculation of uptake using volumetric tools is closer to reality than in the 2D approach. The main reason for this is the appearance of overflow in the sumation. Distinguishing nodes in conglomerates seems also to be easier with the 3D method. As a summary, despite the longer time for evaluation the 3D quantification of uptake is superior than the 2D evaluation and seems to be the right choice towards quantitative imaging with SPECT/CT. In-ABY-025 with the previously evaluated tracers  111 In-DOTA-Z HER2:342-pep2 and  111 In-MMA-DOTA-Z HER2:2395 -Cys. Results ABY-025 was labelled with quantitative yield already after 0.5h of incubation and the conjugate was stable when incubated in complete cell media at 37ºC for 24h. The radiolabelled conjugate retained capacity for specific binding to HER2expressing cells. In SKOV-3 xenografts, 111 In-ABY-025 showed excellent targeting capacity and the tumour uptake was specific (Table 1) . The blood clearance was rapid resulting in a tumour-toblood ratio of 6.3 already 0.5h p.i. which was further increased for later time points reaching 88 at 4h p.i. The biodistribution pattern of 111 In-ABY-025 was in very good agreement with the compared tracers. Xenografts were clearly visualized both 0.5h and 4h p.i. Conclusions Despite profound re-engineering of the Affibody molecule, the 111 In-ABY-025 biodistribution pattern is in a remarkable good agreement with the other compared tracers. In vivo, 111 In-ABY-025 shows high and specific targeting capacity to HER2 with rapid blood clearance, leading to high tumourto-organ-ratios and very good imaging contrast. Delivery is still the major hurdle in RNAi therapy. Due to instability of siRNA and rapid excretion upon systemic injection, most of the clinical trials involving siRNA based drugs apply local administration to the eyes targeting macular degeneration and diabetic retinopathy or direct delivery to the brain or the lung. The lung with its vast surface area and strong perfusion is indeed well suited for drug uptake concerning small, hydrophobic molecules. It is, on the other hand, only to a limited extent permeable for large, hydrophilic biopharmaceuticals, such as siRNA. Yet, successful local therapy, e.g. protection from SARS infection, inhibition of RSV and influenza A virus replication has been reported. In our study, we have investigated how formulation of siRNA with polyethylene imine (PEI) and polyethylene glycol (PEG) grafted PEI (PEG-PEI) into nanosized complexes influences biodistribution, absorption and clearance of vector and load after intratracheal instillation. These parameters were studied by non-invasive nuclear imaging and were compared for PEG-PEIs of different grafting degrees. Non-invasive imaging allows for investigation of biodistribution in the same animal at different time points. SPECT images show slow elimination of the 111In-DTPA-labeled material. After 24 hours, radioactive signal can still be observed in the mounth and the upper trachea. The kidneys are slightly visible. Another 24 hours later, radiolabeled material is excreted via the kidneys, and the liver becomes slightly visible. The strongest signal is observed in the lung, and only in the lower trachea radioactive material is still present. To quantify biodistribution of radiolabeled siRNA and polymers, organs were dissected 48 hours after treatment showing that, depending on the polymer, still 5-22 % of the vector and 1-11 % of the load is present in the left lung, which -for anatomical reasons -was filled with a bigger part of the polyplex solution. The first-pass effect, which is very prominent after i.v. injection, was decreased to about 5 % uptake of labeled polymers and a negligible percentage of siRNA by the liver. PEI and PEG-PEI polyplexes seem to be suitable for local sustained release siRNA delivery. Clearance of radioactive material was observed to be much slower than after systemic administration, the first-pass effect was circumvented, local concentrations were high for 48 hours and no pathologic effects in the lung were observed histologically. Knock down efficiency in GFP mice after instillation of siGFP/(PEG-)PEI polyplexes, which was observed qualitatively, remains to be quantified.

Introduction Transplantation of endothelial progenitor cells to assist angiogenesis has been evaluated in models of myocardial infarction. Cell tracking with the use of radiolabels like 111In have been instrumental in determining the retention of labeled cells at the infarction site. However, cellular safety limits of such radiolabels must be established to ensure that transplanted cells remain functional. We describe the dose dependent effects of 111In cytotoxicity on canine endothelial progenitor cells (cEPC) in vitro for autologous transplantation of cEPCs in a canine model of myocardial infarction. Methods Peripheral blood was taken from one female mongrel dog (30 ml) and mononuclear cells were isolated using density gradient centrifugation. Isolated cells were cultured in EBM-2 media supplemented with 10% FBS and penicillin/streptomycin and adherent cEPCs were culture expanded up to passage 9. On day 0, cEPCs were collected and divided into 4 groups consisting of 3 radiolabeled groups and a control group (5.79x106 cells/group). Radiolabeled groups were labeled with 111In-tropolone for 30 minutes, washed twice with PBS, and cell pellet and supernatant activity was determined using a dose calibrator. Cell proliferation was assessed using the MTT assay at days 1, 4, 8, and 10 and cell counting with a hemacytometer days 1, 4, and 9. Viability was assessed using the trypan blue exclusion assay days 1, 4, and 9. Results Labeling efficiency for each radiolabeled group of cells was 94.3, 92.8, and 91.2% with cellular activities of 0.036, 0.08, and 0.198 Bq/cell respectively. MTT results demonstrated that cEPC proliferation was affected by 111In in a dose-dependent manner with the 0.198 Bq/cell group being significantly different from control at all time-points (p<0.05). Lower cellular doses indicated a slight lag at early time-points after labeling (day 1 control vs. 0.08, p<0.01; day 4 control vs. 0.032 and 0.08 p<0.05), however were not significantly different from control at later time-points. Cell counting data also confirmed these results. Cell viability remained between 80-100% over the observation period. Conclusion Dose-dependent effects of 111In were seen on cell function such that cEPCs exhibited significantly slower proliferation rates at the highest dose. Viability data at late time-points suggest little direct effects from 111In at the levels tested over the period of observation. These data suggest the importance of safe cellular limits for angiogenic therapies using labeled transplanted cells. Aim: Reporter genes have become a standard tool in various molecular biology protocols with the aim of determining the location, duration and extent of gene expression within living subjects. However, for the brain no successful PET reporter systems are available with low endogenous background gene expression and good blood-brain-barrier (BBB) penetration of the PET probe. The aim of this study was to develop a new PET reporter gene system which can be applied to the brain. The type 2 cannabinoid receptor (CB2) has a very low brain expression in physiological conditions and CB2 PET radioligands crossing the BBB were recently developed.

We constructed an adeno-associated viral vector (AAV) transfer plasmid encoding human CB2, harboring a point mutation at position 80 (D80N) referred to as CB2(D80N), as such or in combination with enhanced green fluorescent protein (eGFP) or firefly luciferase (FLuc). Two rats were stereotactically injected with 5 µl of AAV-eGFP-T2A-CB2(D80N) in the right striatum and 5 µl of AAV control vector in the left striatum. At different time points (6, 13, 18 and 96 days) after stereotactic injection of the AAV, a selective 11 C-labeled CB2 inverse agonist (2,3dichloro-phenyl)-[5-[ 11 C]methoxy-2-methyl-3-(2-morpholin-4-yl-ethyl)-indol-1-yl]methanone was injected intravenously and dynamic µPET images (Focus 220, Siemens) were acquired. Timeactivity curves (TAC) and parametric binding potential maps were determined. The animals were sacrificed and perfused and double immunohistochemical staining against CB2 and eGFP of the brain sections was performed. Results: The observed CB2 binding potential increased over time and reached a maximum in right striatum at 18 days after vector injection in the brain. The timeactivity curves persistently expressed an increased uptake in right striatum compared to control left striatum and cerebellum. Immunohistochemical analysis showed colocalization of both CB2 and eGFP in the right striatum. In contrast, only eGFP expression was seen in the contralateral hemisphere. Conclusion: We have successfully developed a new PET reporter gene system consisting of an adeno-associated viral vector expressing the CB2 receptor as the reporter gene which can be quantified for at least 3 months. Purpose: Acute myocarditis is one of the most challenging diagnosis in cardiology, due to its wide non-specific clinical, electrocardiographic and echocardiographic features. SPECT using 111 Inantimyosin-antibodies (specific for cardiomyocytes death) used to be accurate for this purpose but is no longer available. Our aim is to evaluate the sensitivity of 99m Tc-Annexin A5 (ANX) scintigraphy during acute and chronic phase of experimental autoimmune myocarditis. Methods : Myocarditis was induced by injection of purified rat cardiac myosin in 24 Lewis rats who were then studied on day10, day15, day20, 1 month, 3 months or 6 months after immunization by echocardiography and ANX imaging (microSPECT/CT Biospace Lab). SPECT/CT images were qualitatively and quantitatively analyzed, using myocardial-to-muscle activity ratio (MMR) on axial slices. In vivo imaging data were compared to autoradiographic and histological findings (Hematoxilin Eosin, Sirius Red) in terms of location, extent, and intensity of lesions. Results: Both echography and ANX SPECT/CT were negative in all rats on day10 and in 2 of 4 rats at 6months after immunization. ANX-SPECT/CT was positive in 16 of 17 rats from day15 to 3 months after immunization, while echocardiography was normal in 6 of them with limited (<3/17 myocardial segments) histological lesions. MMR was 7.9±2.1 in the 11 rats with >3 segments lesions, 5.6±1.1 in the 6 rats with <3segments lesions, versus 3.8±0.7 in 8 controls (p<0.01 and p<0.03). It peaked at 21days then decreased. Six months after immunization, 2 of 4 rats had dilated hypokinetic fibrotic ventricles with positive ANX imaging in 1 case. On autoradiography of axial myocardial sections, ANX activity was located in areas of mixed dead myocytes and inflammatory cells. Conclusion: ANX-SPECT/CT was positive during acute and chronic (3 months) phase of immunoallergic myocarditis in rats. This suggests potential clinical role of ANX imaging for the detection of acute and chronic active myocarditis. Objectives : We have radiolabelled with Tc-99m a biotinylated peptide (called collagelin) which mimics the collagen binding site of glycoprotein VI and specifically binds to collagen in vitro. Our aim was to test the ability of 99mTc-collagelin (Coll) to target collagen in vivo using a rat model of myocardial fibrotic scar and a mouse model of pulmonary fibrosis. Methods : Myocardial infarctions (MI) were induced after thoracotomy by coronary ligature in 8 Wistar rats. Lung fibrosis was induced in 2 male C57BL/6J mice by intratracheal administration of bleomycin ( Bellon, Aventis, France). One month after coronary ligature, and 14 days after bleomycin tracheal instillation, alive animals were IV injected either with Coll (70MBq in 8 rats, 8MBq in 5 mice) or with irrelevant peptide (IP in 8 rats and 5 mice). Then planar and SPECT thoracic images were obtained 1-2h after tracer injection , using a dedicated small animal system. Heart-to-lung activity ratios (HLR), and lung-to-muscle activity ratios (LMR) were calculated on planar images in rats and mice respectively. Then frozen axial heart and lung sections were used for quantitative autoradiography, and histology (hematoxilin eosin, Sirius red). The whole procedure was also performed in 6 sham-operated rats, and 7 saline serum instillated mice. Results : After IV injection Coll demonstrated fast blood clearance (half life: 5±0.5 min), early high gallbladder then bowel excretion, low liver and low renal uptake. No thyroid or gastric uptake was observed until 6h post-injection. Significant Coll uptake was observed in the cardiac area of all but 1 of the rats with MI scars, compared to sham-operated rats (n=6 (mean injected mass = 180 ng; range 5-400 ng) and sacrificed at 10 or 60 min post injection. The organ-specific biodistribution of radioactivity was measured as a percentage of the injected dose per gram of tissue (% ID/g). For autoradiographic analysis, the pancreases were cut into 20-µm thick cryosections and the regions of interest were outlined on digital images using image analysis software. To establish histological references for the analyzed regions, the same or adjacent sections were subsequently stained with haematoxylin and eosin. Insulin and VMAT2 antibody staining defined VMAT2 expression in rat islets. Radioactive metabolites in the pancreas were analyzed by radio thin layer chromatography. For in vitro autoradiography studies, 20-µm thick cryosections of rat pancreas (and brain and adrenal gland as references) were incubated with various concentrations of [11C]DTBZ.

[11C]DTBZ uptake at 10 min in whole pancreas was 3.0 ± 0.6 and in blood 0.20 ± 0.02 % ID/g, and at 60 min 3.0 ± 0.5 and 0.10 ± 0.01 % ID/g, respectively.

Tissue measurements and autoradiographic analysis of pancreas slices showed that radioactivity uptake in the pancreas was heterogeneous. At 10 min p.i. the uptake was 2-fold higher in the head than in the tail of the pancreas. No difference in the amount of unchanged tracer was found between the different parts of pancreas. The ex vivo and in vitro autoradiography, combined with histological stainings, demonstrated that radioactivity uptake did not accumulate in islets.

Previous studies have suggested that quantification of VMAT2 expression in beta cells using [11C]DTBZ represents a method to estimate changes of beta cell mass. Our results suggest that initial regional uptake of [11C]DTBZ is largely determined by local vascularization of pancreas. Unspecific exocrine uptake then dominates and specific endocrine uptake is not observed, at least within the time frame achievable with the short lived [11C]DTBZ. Introduction: When considering the pathophysiologic basis of both the degenerative and tumoural pathologies of cartilage, proteoglycans (PG) appear as one of the primary targets for the degradation and proliferation processes respectively. Our lab develops a "cartilage imaging strategy" with the 99m Tc-NTP 15-5 tracer that selectively binds to cartilage PG in vitro and in vivo.

We have assessed the pertinence of 99m Tc-NTP 15-5 radiotracer for cartilage SPECT imaging in: (i) healthy animals, (ii) animals developing osteoarthritis, and (iii) animals with primary and recurrent grade II orthotopic chondrosarcoma. Considering pathological animal models, 99m Tc-NTP 15-5 imaging was performed at regular intervals after pathology induction and tracer uptake followed as a function of time. 99m Tc-NTP 15-5 imaging was compared with 99m Tc-HMDP scintigraphy. Results: In healthy animals, a high and specific accumulation of 99m Tc-NTP 15-5 was observed in cartilage (about 5.5 +/-1.7 % of ID/g of tissue at 15 min after iv injection), with a highly contrasted joint imaging being obtained in all animal species studied (i.e. rabbit, guinea pig, rat and also mice using high resolution 1mm-pinhole SPECT acquisition). In the meniscectomized guinea pig model of osteoarthritis, 99m Tc-NTP 15-5 imaging (being performed over 6 months) allowed in vivo the assessment of PG changes associated to both the hypertrophic and decompensation responses of degenerative cartilage. In the orthotopic swarm rat chondrosarcoma models (both the primary growth and recurrent models) 99m Tc-NTP 15-5 imaging evidenced a significant uptake of the tracer at the tumoural site at very early stage, with the tracer uptake being strongly correlated with tumour growth. It should be mentionned that 99m Tc-HMDP imaging was negative during the whole study, even at the later stage of tumoural development or recurrence. Conclusions: These experimental results in relevant animal models underlined the potential of Background: 89Zr-rituximab-PET/CT combines the high sensitivity of PET/CT with the specificity of the chimeric monoclonal antibody (mAb) rituximab for the CD20-antigen expressed on the surface of CD20+ B-cell non-Hodgkin's lymphoma (NHL). Zirconium-89 (89Zr) is a positron emitter with a half-life of 78.4 hours, which is compatible with the time needed for a mAb to achieve optimal tumour-to-background ratios. The aim of this study was to compare the diagnostic accuracy of 89Zr-rituximab-PET/CT with 18FDG-PET/CT in patients with CD20+ B-cell NHL. Materials and Methods: Six patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma (1 mantle cell and 5 follicular lymphomas) were included in this study. Similarly to the Zevalin® treatment schedule, each patient received a first infusion of unlabelled (cold) rituximab at 250 mg/m² followed by the injection of 3-4 mCi 89Zr-rituximab and one week later, the same infusion of cold rituximab followed by radioimmunotherapy with 90Y-rituximab (0.3-0.4 mCi/kg). 89Zrrituximab-PET/CT was performed at 4 time points: 1 hour, 24 hours, 3 days and 6 days after intravenous administration of 89Zr-rituximab. A baseline 18FDG-PET/CT was performed 1 to 4 weeks before the 89Zr-rituximab immuno-PET/CT. Standard uptake values (SUV) were assessed for all PET-positive lesions and compared for both tracers. Results: 18FDG-PET/CT revealed 24 hypermetabolic lesions (SUVmax: 8±4, range: 2.1 -15.9) in the 6 evaluated patients. All FDGpositive lesions showed significant uptake on 89Zr-rituximab-PET/CT, with highest SUV on the late images (6 days post injection of 89Zr-rituximab; SUVmax: 8.9±5.3, range: 2,6 -26,1). Linear regression analysis of SUV in 89Zr-rituximab-and 18FDG-positive lesions showed a very poor correlation (R2 = 0,14) between the level of CD20 antigen-expression and metabolic activity. Moreover, in 2 out of 6 patients, 89Zr-rituximab-PET/CT revealed 8 supplementary CD20+ lesions which were strictly negative on 18FDG-PET/CT and corresponded to particularly small (≤ 1cm) lymph nodes and mesenteric nodules on CT. Conclusion: 89Zr-rituximab-PET/CT provides an excellent imaging tool for accurate quantification of CD20 antigen-expression, which is of particular interest for dosimetry as a prelude to radioimmunotherapy with 90Y-Rituximab. The preliminary results of this pilot study suggest that 89Zr-rituximab-PET/CT is more accurate than 18FDG-PET/CT for the detection of viable lymphoma in patients with predominantly indolent NHL. Purpose: To evaluate the diagnostic accuracy of 18F-FDG-PET/CT in patients with primary extranodal lymphoma(PEL). Methods: All patients presenting to our institution over a 5 year period with a clinical/histological diagnosis of PEL who underwent 18F-FDG-PET/CT scanning were included. Of 30 patients (15 male,15 female, mean age 60), 9 had gastrointestinal PEL, 3 each had pulmonary, cutaneous and bone PEL, 2 each had brain, orbital, breast and pancreatic PEL, and one each had thyroid, testicular, parotid and muscular PEL. Of 45 PET/CT scans, 19 were for staging, 13 for monitoring post-therapy response and 13 to look for suspected recurrence. Ability to detect PEL, exclude secondary nodal lymphoma, detect recurrence and assess treatment response was recorded. Final diagnosis was based on histology/cytology, and clinical and imaging follow-up (median 52 months, range 8-78 months). Results: Staging PET/CT correctly detected PEL and excluded secondary spread from nodal lymphoma in 16/19 cases. In one case of orbital lymphoma PET/CT confirmed secondary involvement. In one DLBCL of small bowel, PET/CT failed to detect bone marrow disease. Findings were indeterminate in 1 case (duodenal uptake could not be resolved as inflammatory or neoplastic). In the post-treatment response group, PET/CT was true positive(TP) in 3 patients, true negative(TN) in 8, false positive in one(small bowel uptake due to fibrosis/granulation tissue), and indeterminate in one(pulmonary uptake could not be resolved as inflammation/residual lymphoma). Of 13 scans for recurrence, 4 were TP, 7 TN and 2 were indeterminate(one showing acute gastritis or recurrent lymphoma in a patient with treated lung PEL, the other either post-treatment inflammation or recurrence in brain PEL). Conclusions: 18F-FDG-PET/CT showed a high degree of accuracy in staging PEL and assessing both disease recurrence and post-treatment response. This is important as treatment for localized PEL, advanced-stage PEL and secondary extranodal involvement by systemic lymphoma differs radically. PELs often show preferential spread to other extranodal organs, where they may be difficult to visualize by cross-sectional imaging. The additional information provided by PET/CT is valuable in this scenario. AIM Our study aimed to evaluate if standardized uptake value (SUV) discriminates well between aggressive and indolent lymphomas, and if there is a correlation between the SUVmax, as an indicator of cellular glucose uptake, and Ki67, as a cellular proliferation indicator, in non-Hodgkin's lymphoma (NHL). MATERIAL & METHODS We retrospectively studied 177 patients (54% males, 46% females, average age 50 years, SD 19,4) with biopsy-confirmed lymphoma, typified according to the 2008 WHO Classification, who underwent PET/CT for staging. We noted only the highest SUVmax value in patients with more than one pathological FDG accumulation. In 72 cases of NHL, Ki67 proliferative index was also recorded. For the statistical analysis we used the receiver operating characteristic (ROC) curve, Student-t test, and the 1-way analysis of variance (ANOVA) with a post hoc lowest square difference (LSD) or Tamhane test. Significance was obtained when p≤0.05. RESULTS The mean SUVmax value was higher in aggressive (n=109, mean SUVmax=12.2) than in indolent (n=68, mean SUVmax=5.4) lymphomas (P<0.01). In the NHL group (n=129), we found also the same difference when comparing aggressive (n=61, mean SUVmax=14.5) and indolent (n=68, mean SUVmax=5.4) (P<0.01). The ROC curve showed that SUVmax of 8 discriminates aggressive from indolent lymphoma patients with a sensitivity and specificity of 79% in NHL.

%Ki67 n mean SUVmax n mean SUVmax Aim: Fluorine-18 Fluorodeoxyglucose (FDG) PET-CT examination is widely used in the primary staging of lymphoma patients. Although it has shown to be superior to conventional staging in detection of nodal and extranodal involvement, its role in detection of bone marrow involvement needs further evaluation. In this study we aimed to evaluate role of FDG PET-CT in detection of marrow involvement of Hodgkin's and non-Hodgkin's lymphoma. Material-methods: FDG PET/CT images of 62 lymphoma patients who were examined for primary staging purposes and had bone marrow biopsies were analyzed. Patients taking any chemotherapeutics or bone marrow stimulants before the PET/CT scan were excluded. We measured bone marrow FDG uptake by drawing cubic volume of interests over lumbar 3rd, 4th and 5th vertebrae and calculated the mean standardized uptake values (bmSUV). Focal pathological findings were excluded from this quantitative analysis. Additionally, mean SUVs were calculated for mediastinal blood pool (bloodSUV) and liver (liverSUV). Receiver operating characteristics (ROC) curve analyses were used to assess the diagnostic accuracies of bone marrow uptake using bmSUV values, bmSUV/bloodSUV and bmSUV/liverSUV ratios. Bone marrow biopsy findings were used as the diagnostic reference. Results: The study group involved 19 Hodgkin's and 43 non-Hodgkin's lymphoma patients. Bone marrow biopsy showed infiltration in 13 of 62 patients (21%) and negative in 49 (79%). ROC curve analysis using bmSUV produced an area under curve (AUC) value of 0,722 (p=0,014). With a cut-off value of bmSUV ≥ 2,5 FDG PET-CT demonstrated 69% sensitivity and 63% specificity in the detection of bone marrow involvement. AUC value was slightly better (0,754 with p=0,005) for the bmSUV/ bloodSUV ratio and slightly lower (0,706 with p=0,023) for bmSUV/ liverSUV. Using a cut-off value of bmSUV/bloodSUV ≥ 1,8 increased specificity to 69% without a change in sensitivity. Conclusion: Quantitative analysis of FDG PET-CT images showed moderate sensitivity and specificity in diagnosis of bone marrow involvement in lymphoma patients. Using bone marrow to blood pool FDG uptake ratio instead of bone marrow 18F-FDG uptake increased the specificity value. 

The role of FDG PET and PET/CT in initial staging of childhood lymphomas the metabolic activity of tumor cells and was proven useful in staging of lymphomas in adults. Increased metabolic activity frequently precedes the delayed morphological and anatomical changes and metabolic changes may occur even if anatomic size does not change significantly.Whole-body PET and PET/CT can also detect lesions at unexpected sites. The aim of our study was to assess the usefulness of PET and PET/CT for initial staging of pediatric lymphomas and its possible impact on the clinical management. Materials and methods: Over a period of 5 years eighty-six children and adolescents with lymphoma (58 with Hodgkin's lymphoma, 28 with non-Hodgkin's lymphoma) had complete diagnostic work-up including FDG-PET (31 pts.) or PET/CT (55 pts.) and were included into this study. Mean age was 15 years (4-19). PET and PET/CT findings were correlated with standard staging methods (CSM) including CT, ultrasound, and bone marrow examination. Discordant findings were verified by MRI and followup radiographic studies including PET and PET/CT. Results: There were concordant findings in 57/86 (66%) children. In 26 patients PET and PET/CT revealed 40 additional lymphoma manifestations (22 normal-sized lymph nodes, 13 focal bone marrow infiltrates, and 5 extranodal lesions) and correctly upstaged 13 of 86 children (15%). Only two out of 86 patients (2%) were not accurately staged by PET, when PET failed to visualize diffuse bone marrow infiltration (extent of 15% cells) in 1 patient (CT negative), and missed small pulmonary metastases (≤6 mm) in 1 child, that were correctly described by CT component of integrated imaging. Compared with CSM, pre-treatment PET had significantly higher sensitivity (97% vs. 83%), specificity (100% vs. 89%), and significantly higher accuracy (98% vs. Objective The purpose of this study was to observe the biologic characteristics of Gd-DTPA-Dimeglumine of magnetic resonance contrast enhancer labeled with technetium-99m. Method The labeled compounds was prepared by reducing 99m Tc in the presence of Gd-DTPA-Dimeglumine with stannous chloride. The labelling efficiency and stability of 99m Tc-Gd-DTPA-Dimeglumine and 99m Tc-DTPA were measured by thin paper chromatography. The plasma protein binding rates were measured by the trichloroacetic acid method, the biodistribution in mice was observed by the blood sampling and major organs that were taken out from mice at 1min, 5min, 10min, 15min, 30min, and 60min after intravenous injection of labeled compounds, and renal dynamic scintigraphy in rabbit were administrated. All of the experimentations compared with 99m Tc-DTPA. Results The labelling efficiency of 99m Tc-Gd-DTPA-Dimeglumine was 97% and stable at room temperature within 6h. The plasma protein binding rate of 99m Tc-Gd-DTPA-Dimeglumine and 99m Tc-DTPA were 3.48±0.24% and 2.25±0.21%, respectively, and have significant difference.

Statistical indicated that the amount of 99m Tc-Gd-DTPA-Dimeglumine deposited in brain, heart, lung higher than that of 99m Tc-DTPA at 1min after injection, and 99m Tc-Gd-DTPA-Dimeglumine deposited in muscle , blood, heart deposited higher than that of latter at 5min, 10min, 15min respectively. Renal dynamic scintigraphy showed that two labeled compounds were quickly excreted by kidney, and the time to peak less than 5min, the half time of clearance is about 10min. Conclusion The magnetic resonance contrast enhancement of Gd-DTPA-dimeglumine may be labeled with with technetium-99m. 99m Tc-Gd-DTPA-Dimeglumine may be a significant way to study its biodistribution in vitro and in vivo. 99m Tc-Gd-DTPA-Dimeglumine could be detected with both SPECT and MRI which increase imaging resolution and sensitivity.

Facile synthesis of DO3MP-AME-DO3MP and its preclinical evaluation as multidentate imaging agent for skeletal metastases using SPECT A. Datta, J. Tanwar, P. Srivastava, K. Chuttani, A. K. Mishra; Institute of Nuclear Medicine and Allied Sciences, Delhi, INDIA.

Aim: A variety of bone-seeking radiopharmaceuticals have been used in attempts to diagnose and palliate the pain of patients with skeletal metastases. The phosphorus based tracers especially phosphonate compounds are routinely used for this purpose. The presence of uncoordinated phosphonate oxygen atoms allow a mechanism for absorption of the complexes on the surface of newly formed hydroxyapatite. The diagnostic imaging of the lesions before the therapy is useful in giving information about the extent of damage and radiation doses to be delivered during therapy. The metastable radionuclide 99mTc has become the mainstay of diagnostic nuclear medicine. Design of a phosphonate derivative having diagnostic application in bone imaging is the aim of our research. Methods: As part of our efforts to explore the application of chelating agents, this work describes the potential of 99mTc-DO3MP-AME-DO3MP as diagnostic pharmaceutical by evaluating its deposition in bony tissues after the synthesis and radiolabeling of 10 -bis(acetamido)ethane-bis[1,4,7-tri(methylenephosphonicacid)-1,4,7,10tetraazacyclododecane (DO3MP-AME-DO3MP). 1,4,7,10-Tetraazacyclododecane was converted to tris(t-butyl) ester of 1, 4, 7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane. Fourth unsubstituted arm was bound with ethylene diamine based linker and was attached to one more unit of 1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane to give the compound , 10bis(acetamido)ethane-bis[1,4,7-tri(carboxymethane)-1,4,7,10-tetraazacyclododecane (DO3A-AME-DO3A). Finally its phosphonic acid derivative, DO3MP-AME-DO3MP, was synthesized with PCl 3 . Results: DO3MP-AME-DO3MP was synthesized and characterized by NMR spectroscopy.

The radiolabeling efficiency was found to be > 97% and the stability in serum indicated that 99mTc remained bound to the chelate, DO3MP-AME-DO3MP up to 24h. Blood clearance showed a quick wash out from the circulation and biological half life were determined. Biodistribution characteristics of 99mTc-DO3MP-AME-DO3MP were examined in BALB/c mice and it shows prominent bone localization. The drug was excreted mainly through renal routes. The scintigraphic images of 99mTc-DO3MP-AME-DO3MP in rabbit showed rapid accumulation of radioactivity in bone. Within 30 min the compound 99mTc-DO3MP-AME-DO3MP was localized in the whole skeleton rapidly. The images also show that non-osseous tissue uptake of 99mTcchelate was minimal and when assessed with its rapid blood clearance, accounts for the low soft tissue activity. Conclusions: 99mTc-chelated DO3MP-AME-DO3MP has high bone accumulation property, since it displays selective uptake in the skeletal system and has low nontarget uptake and rapid nonosseous tissue. Therefore, it can be useful in bone metastases pretherapy diagnostic imaging. Attempts are being made to use it for therapeutic purpose with radiometals (β-emitters) like Ho-166, Re-186 and other metal ions. Tc-DO3A-Act-Met as diagnostic pharmaceutical by evaluating its deposition in cancerous tissues after the synthesis and radiolabeling of 4-methylsulfanyl-2-[2-(4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetylamino]-butyric acid, DO3A-Act-Met. 1,4,7,10-Tetraazacyclododecane was converted to tris(t-butyl) ester of 1, 4, 7tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane. Fourth unsubstituted arm was bound with chloroacetyl derivative of methionine methyl ester to give the compound, 4-methylsulfanyl-2-[2-(4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetylamino]-butyric acid, DO3A-Act-Met. Finally, the compound is radiolabeled with 99m Tc for scintigraphic studies. Results: DO3A-Act-Met was synthesized and characterized by NMR and Mass spectroscopy. Radiolabeling efficiency with 99m Tc was found to be > 97% and the stability in serum indicated that 99m Tc remained bound to DO3A-Act-Met up to 24h. Initial investigation of blood clearance showed a quick wash out from the circulation and biological half life were determined. Biodistribution characteristics of 99m Tc-DO3A-Act-Met were examined in BALB/c mice and it shows prominent tumor (EAT) localization. The drug was excreted mainly through renal routes and the accumulation of 99m Tc-DO3A-Act-Met in tumor was determined at various time intervals.

99m Tc-DO3A-Act-Met has high tumor (EAT) accumulation property. Further investigation on the BMG glioblastoma is being carried out. Attempts are also being made to use the cavity of 1,4,7,10-tetraazacyclododecane to introduce 68Ga and 64Cu to determine the application of DO3A-Act-Met in PET imaging. Aim: Multidrug resistance (MDR) is a condition characterized by the presence of cross-resistance to several non-structurally related drugs, representing one of the major setbacks to the success of chemotherapy. One of the mechanisms responsible for MDR is the overexpression of efflux pumps such as P-glycoprotein (Pgp), multiple resistance-related protein 1 (MRP1) and lung resistance-related protein (LRP). These proteins confer resistance to a similar spectrum of substrates, despite their different intracellular locations and extrusion mechanisms. Verapamil is a L-type calcium-channel blocker, ¬known as a substrate for Pgp, reversing its activity. L-Buthionine-sulfoximine (BSO) is a γ−glutamylcysteine synthetase inhibitor and can be used as blocker for cellular MRP1. In this study we aim to compare transport kinetics for a resistant human colorectal adenocarcinoma cell line, in the presence and absence of two MDR reversers, verapamil and BSO, through 99mTc-Sestamibi. Methods: MDR proteins expression was evaluated in resistant (ATCC-LS1034) and sensitive (ATCC-WiDr) human colorectal adenocarcinoma cell lines. Cytoplasmatic and membrane Pgp, MRP1 and LRP, was analyzed by flow-cytometry. Pgp expression was also analyzed using western blotting techniques. Cellular transport kinetics was analyzed in the presence and absence of MDR modulators, verapamil and BSO. Retention studies were performed after cell incubation with the previously referred drugs, for different time intervals (10 and 60 minutes) and concentrations (10, 25, 50 and 100 µM) with 99mTc-Sestamibi. For that cells were incubated for 60 minutes, washed after and resuspended with 99mTc-Sestamibi-free medium. Samples were collected and cell metabolism stopped at different timepoints in order to obtain retention percentage, which was measured by gamma-counting adjusted for 140 keV. Retention studies were also performed using LigandTracer® Yellow (Ridgeview Instruments AB, Uppsala-Sweden), an equipment that enables real-time measurements in order to obtain continuous retention curves. Data was analyzed using appropriate software. Results: Pgp and LRP expression was significantly higher (p<0.05) in resistant cells when compared to the sensitive ones, although MRP1 being also expressed. Western blotting analysis confirmed flow-cytometry results. 99mTc-MIBI retention percentage was significantly higher (p<0.05) in the resistant cell line when compared with the sensitive one for all time-points considered. In resistant cells incubated with MDR modulators there are no statistically significant differences (p>0.05) when all points of the retention curves are considered. However, in the first minutes that there are differences among the MDR modulators used. Conclusions: The data obtained until now suggest that with the modulators evaluated, they must be used immediately before the cytotoxic drug administrated. 

Improved diagnostic accuracy for neuroendocrine tumours using fused SPECT/CT (low dose) with Tc-99m-Tektrotyd were investigated for staging of disease before (6 patients) or after (5 patients) surgery of primary tumour. STRS was performed in all patients at 1h and in 5 patients also at 3h p.i. of 555 MBq Tc-99m-Tektrotyd. All patients underwent wholebody scan (AP and PA) and SPECT/CT (low dose) imaging of thorax, abdomen and in selected cases of head and neck also. SPECT images were first interpreted alone and then re-evaluated with the addition of fused SPECT/CT images. Results: Abnormal SPECT findings were reported in 23 sites (primaries,4; metastases,19) in 10 patients. CT anatomical maps provided more precise anatomical localization than SPECT alone in 9 of these abnormal findings. SPECT/CT hybrid imaging allowed the characterization of the significance of 5 lesions found with diagnostic CT and enabled the exclusion of tumour disease in 3 of the sites with abnormal tracer uptake. The minimum size of the lesions that were detected was 6 mm. Conclusions: The imaging properties of Tc-99m and the one-day imaging protocol with Tc-99m-Tektrotyd offer opportunities for more widespread application of STRS. (2), glioblastomas (7), oligodendroglioma grade II (1) and oligoastrocytoma grade II (1). The patients were treated with chemotherapy alone (n=9), radiotherapy (n=4) or chemotherapy combined with radiotherapy (n=2). 185 MBq 18-F-FET were injected i.v., followed by PET/CT imaging of the brain (Philips Gemini GXL) 30 minutes later. Each patient was examined two times by a FET PET between July 2005 and February 2009. The mean time lag was 10 (1 to 36) months. A visual interpretation with a semi-quantitative analysis (SUV) was performed. The patients were classified into responders and nonresponders. The results were compared to the findings on MRI. A stable disease was concerned to be a response to therapy. Results: In 14 of 15 (93%) patients FET PET results were concordant to the MRI changes. We found 7 patients in the responder group and 7 patients in the nonresponder group. In one patient (7%) FET PET showed a response, while MRI suggested a progression. The mean SUV in the responder group decreased by 31% (0 -65%) and increased in the nonresponder group by 89% (19 -217%). Conclusion: The FET PET results were concordant to the MRI results in the vast majority of patients, but one patient under newly initiated Bevacizumab therapy showed early metabolic response to chemotherapy while the structural response has to be awaited. FET PET and MRI are considered complementary modalities. They should be performed concerted in patients with brain tumors, especially because of the ability of FET PET to show metabolic response even before structural changes become detectable. Tumour delineation for therapy planning is normally related to non-18 FDG-PET tracers since normal brain has a high metabolic uptake of 18 FDG. Nevertheless, delayed 18 FDG-PET has shown better contrast of tumour to normal brain uptake (T/N) ratio. Objective To compare several strategies for tumour delineation based on quantitative criteria applied over dual time point 18 FDG-PET images. Materials and methods An automated tumour segmentation method was designed based on the differences between standard and delayed 18 FDG-PET images. Four different segmentation criteria were considered: any SUV increase, SUV increase greater that 10%, any T/N ratio increase and T/N ratio increase greater that 10 %. In order to validate the paradigm, ten patients with suspected glioblastoma multiforme recurrence and uncertain MRI findings were studied. All patients underwent a dual time point 18 FDG-PET study, with standard images acquired at a median of 46.5 minutes (38 to 56) after injection and delayed images acquired at a median of 343.2 minutes (229.8 to 387.0) after injection. A 11 C-Metionine-PET study was also performed. In order to assess comparisons on a voxel basis, parametric images of SUV and T/N ratio were obtained and images from each subject were registered and spatially normalised (SPM2). Tumour extension was analysed attending to each criterion, and compared to the volume segmented over the 11 C-Methionine-PET, considering a T/N ratio of 1.4 as threshold for malignancy. Results All tumours showed areas with T/N ratio increase greater that 10% between early and delayed 18 FDG-PET. Besides, 9 tumours presented areas with SUV increase, and 8 lesions presented a SUV increase greater than 10%. The volume defined with T/N ratio increase on dual time 18 FDG-PET was similar (1/10) or smaller (9/10) than the volume delimited over 11 C-Methionine-PET. SUV increase based criteria yielded smaller tumour extension than T/N ratio criteria in 9/10 patients. Therefore, all criteria considered were too restrictive in segmenting the tumour extension. However, in most patients (8/10) the segmented volume matched with the highest uptake in 11 Aim: Previous FDG-PET studies suggest that cerebral glucose metabolism in subjects with neurofibromatosis type 1 (NF1) is reduced specifically in the thalamus. However, these studies are limited by small sample size and poorly matched control groups. In addition, they did not attempt to explain this specific effect. The aim of the present study was to analyze cerebral FDG uptake in a large sample of adults with NF1 compared to a well-matched control group. In order to test the hypothesis that reduced thalamic activity in NF1 is caused by nerve-tumor-related reduction of peripheral input due to PNF/MPNST, thalamic FDG uptake was tested for correlation with total tumor burden. Materials and Methods: Whole-body FDG-PET/CT including the brain had been performed in 30 NF1 subjects for detection of MPNST. Brain FDG uptake was normal by visual inspection in 24 subjects who were included in the present analysis (14 females, 37.9±16.2 years). Twenty-four control subjects were selected in reverse chronological order using a matchby-subject approach with respect to gender and age. FDG-PET/CT had been performed for a non-NF1/non-CNS oncological indication. Subjects with any finding in the brain were excluded. NF1 subjects and controls did not differ with respect to gender, age, blood glucose level, or FDG dose. Individual brain FDG uptake images were stereotactically normalized using SPM2, and scaled to a common median uptake value within a predefined gray+white matter mask. Scaled FDG uptake was compared voxel-by-voxel between the NF1 group and the controls at the uncorrected significance level a=0.001. VOI-based analysis was performed using the thalamus VOI of the AALatlas. Total tumor burden was quantified in 8 NF1 subjects from whole-body MRI. Results: Voxelbased testing revealed a single 6.8 ml cluster of reduced FDG uptake in the NF1 subjects located in the thalamus. There was no increase of FDG uptake in the NF1 subjects. VOI-analysis showed a 7.2% reduction of thalamic FDG uptake in the NF1 group (t =-3.273, df= 46, p=0.002). Total tumor burden ranged between 7ml and 1.4L. Thalamic FDG-uptake did not correlate with total tumor burden (Pearson r=0.241, p=0.612). The power to detect a correlation of r=-0.7 at the 0.05 level was 79%. Conclusion: Adult subjects with NF1 show reduced FDG uptake specifically in the thalamus. Apparently there is no strong association between thalamic FDG uptake and total tumor burden. However, larger sample size is required to further test the hypothesis of impaired peripheral input to the thalamus in NF1. Binding potential (2FA-BP) was calculated using the corpus callosum as reference region. VOI-/SPM-analyses were performed. To assess different cognitive domains, MS and NC were tested with a multiple cognitive test battery (DemTect -5 subtests, WAIS-III, WMS-III, DOT, TMTA/B). T1/T2-weighted MRI were analyzed semiquantitatively for regional cortical and global atrophy. Significance was accepted at p<0.05 (for SPM p<0.001). Results: Compared to NC, in MS 2FA-BP was significantly reduced in frontal cortex (superior, middle, inferior), cingulate cortex (anterior, middle and posterior), temporal cortex (superior, pole, middle, inferior), sensorimotor cortex (supplementary motor area; SMA), parietal and occipital cortex (cuneus) and cerebellum. Compared to NC, MS patients performed significantly worse in cognitive testing such as WAIS-III digit span forward, word list -immediate recall and Wechsler Memory Scale III -immediate recall implicating impaired attention and verbal/working memory. These cognitive measures correlated significantly with reduced 2FA-BP in frontal and cingulate cortex, temporal, parietal and occipital cortex. There was negligible MR-based cortical/global atrophy in MS compared to NC (p>0.3) Conclusion: In early stage MS, there is significantly reduced α4β2*-nAChR binding in frontal and cingulate cortex (anterior, middle and posterior), in temporal, parietal and occipital cortex (cuneus), in sensorimotor cortex (SMA) and the cerebellum. Since these MS patients demonstrate only negligible cortical/global atrophy, these cortical and cerebellar α4β2*-nAChR diminutions may precede significant cerebral atrophy. Furthermore, in early stage MS cognitive testing revealed significant impaired attention, verbal and working memory that are associated with lower α4β2*-nAChR binding especially in the frontal and cingulate cortex, temporal, parietal and occipital cortex. These preliminary 2FA-PET data suggest that α4β2*-nAChR might become a new target for early assessment and drug development of cognitive impairment in MS.

In-vivo diagnosis of atypical Alzheimer disease using pathology-sensitive brain imaging, 11C-PIB and short TE spectroscopy MR imaging in Posterior Cortical Atrophy Neuropsychological testing showed profound deficits in visuospatial function with relatively preserved memory. Cortical 11 C-PIB binding was raised in the frontal, parietal, temporal and occipital cortex compared with the controls(P < 0.000). The PCA 11 C-PIB binding pattern was similar to Alzheimer disease (parietal, temporal and frontal cortex) but retention was higher in the occipital cortex(P < 0.001). Low N-Acetylaspartate (NAA) and elevated Myoinositol (MI) ratios were found in spectra acquired from voxels, which included the posterior cingulate gyrus. Both patients showed regional parietal cortical atrophy; more marked in one case than the other. Conclusion We have demonstrated increased 11 C-PIB retention reflecting raised amyloid in two Posterior Cortical Atrophy patients. Uptake was higher in the occipital cortex compared with typical Alzheimer disease patients, reflecting the pattern of neuropsychological deficit. In addition, brain metabolic MRI profiles showed regional decreases in N-Acetylaspartate (NAA), increases in Myoinositol (MI), known to be associated with AD. Pathology-sensitive in-vivo techniques have the potential to facilitate differential diagnosis of atypical dementia and identify patients who could benefit from specific anti-amyloid therapeutic strategies.

The detection of 18F-FDG foci on carotid bifurcations and on aortic arch is associated with an enhanced risk of subsequent ischemic stroke: a case-control study S. Grandpierre 1 , B. Meneroux 1 , F. Netter 1 , E. Desandes 2 , W. Djaballah 1 , G. Karcher 1 , P. Marie 1 ; 1 médecine nucléaire, CHU Nancy, Nancy, FRANCE, 2 DIM, CAV Nancy, Nancy, FRANCE.

Aims -When documented in atherosclerotic plaques, a high uptake of 18F-fluorodesoxyglucose (FDG) is likely to relate to an inflammatory cells infiltrate and thus, to potentially unstable plaques. However, the relation with an enhanced risk of subsequent ischemic event is not yet established. This case-control study was aimed to determine whether the previous arterial FDG uptake of patients presenting a subsequent ischemic stroke is higher than that of event-free follow-up controls. Methods -We retrospectively included 26 patients, who had been referred to a conventional hybrid FDG-PET/CT imaging for an oncologic indication: (i) 8 case-patients, selected on the basis of a subsequent hospitalization for a documented ischemic stroke, and (ii) 18 event-free controls, who were matched to each case (2 to 3 per case) according to age, gender, type of cancer and date of PET imaging. The baseline clinical data, as well as data extracted from the CT and PET images of carotids and aortic arch, were compared between cases and controls. Results -Compared with controls, the case-patients exhibited: (i) trends toward a higher incidence of previous cardiovascular disease (75% vs. 29%, P=0.06) and a higher number of cardiovascular risk factors (2.6±1.4 vs.1.5±1.1, P = 0.08), (ii) equivalent CT calcium scores on carotids and aortic arch and (iii) higher rates of FDG foci on carotid bifurcations (63% vs.12%, P = 0.02) and aortic arch (75% vs. 26%, P = 0.02). Among the 5 case-patients who had a stroke of Sylvian location, 4 (80%) had FDG foci on ipsilateral carotid bifurcations and short delay times between PET and stroke (from 7 days to 14 months). This delay time was much longer (21 months) for the 5th patient who had no arterial FDG focus. Conclusion -To our knowledge, this case-control study is the first one showing that the detection of FDG foci on carotid bifurcations and on aortic arch are both associated with an enhanced risk of ischemic stroke. Further studies are required to precise the clinical usefulness of hybrid PET/CT imaging in this setting.

Cerebral perfusion changes after carotid endarterectomy, using Tc-99m ECD brain SPECT with voxel-based analysis A. Nocun 1 , M. Wilczyński 2 , J. Wroński 2 , B. Chrapko 1 ; 1 Department of Nuclear Medicine, Medical University of Lublin, Lublin, POLAND, 2 Department of Vascular Surgery and Angiology, Lublin, POLAND.

Purpose: The aim of the present study was to determine preoperative hypoperfusion and perfusion changes after carotid endarterectomy (CEA) in patients with internal carotid artery stenosis. Material. Examined group included 27 patients ( 5 women and 22 men) at the age of 44-80 years with internal carotid artery stenosis 70%. Eight participants had a history of stroke and 16 of transient ischemic attacks (TIA). Preoperative computed tomography (CT) was normal in 15 cases, including 3 asymptomatic patients. Methods. Brain perfusion SPECT with 99mTc-ECD was performed 1-3 days before CEA and 3-5 days after the surgery. Radiopharmaceutical dose was 740 MBq. Brain SPECT was carried out 20-30 min after injection using a rotating, doublehead, large field of view gamma camera (Varicam, GE Medical Systems) equipped with lowenergy, high-resolution collimators. The data were collected in a 128 × 128 matrix through 360° rotation at 3° intervals for 25 s per view. Data reconstruction was performed by filtered back projection with Metz filter. Regional cerebral blood flow was evaluated visually and semiquantitatively using voxel-based analysis with Brain SPECT Quantification software (Compart, Poland). The change of perfusion between basal and control studies was considered significant when relative difference (RD) was higher than 10% in a cluster volume (CV) greater than 10 ml. Results. No side effects were observed after the surgery. Preoperative SPECT was normal in one asymptomatic patient and in one with TIA and normal CT. Hypoperfusion ipsilateral to CEA was seen in 23 cases, including 11 patients with normal CT. Hypoperfusion contralateral to CEA was seen in 14 cases, including 10 patients with normal CT. After the surgery perfusion did not change in 8 patients. Improvement of perfusion was observed ipsilaterally to CEA in 17 cases (CV=10. 2-194.9ml Introduction/background: Haemolytic-Uraemic Syndrome (HUS) is a multisystemic disease clinically characterized by uraemia, thrombocytopenia and haemolytic anaemia and it is the most common cause of acute renal failure in children between 1 and 4 years of age. Besides the kidneys, the central nervous system (CNS) is clinically involved in 20-50% of HUS cases. Common signs of severe CNS injury are seizures, alteration of consciousness, hemiparesis, visual disturbances and brainstem symptoms, with 4-10% of acute mortality. Morphologic brain imaging (CT and MRI) can show structural changes in basal ganglia, cerebellum, thalami and brainstem in 20-60% of HUS cases with severe CSN involvement. Aim: Functional imaging of brain perfusion/metabolism was rarely applied in HUS and aim of the study is to assess brain functional involvement by means of F-18-Fluoro-deoxi-glucose (F18-FDG) brain PET imaging. Methods: Six patients with HUS (3 males, mean age 6 years) were studied in acute phase and after clinical resolution (1-12 months later). Two patients had neurologic symptoms/signs but none deceased for complications. PET/CT brain imaging was obtained 40-60 min after FDG intravenous administration (Biograph TruePoint PET-CT, Siemens, Erlangen, DE). Visual and VOI-based analysis of PET data were performed comparing early and late PET/CT studies. Results: Acute PET/CT study showed a mild symmetric and diffuse impairment of cortical perfusion/metabolism in cerebellum and posterior cortex (parieto-occipital); one patient showed also relevant asymmetric hypometabolism in left temporal cortex. Subcortical involvement was mild and limited to the caudate nuclei. Recovery PET/CT studies showed normalization of perfusion patterns in parieto-occipital cortex and subcortical gray matter, whereas the cerebellum hypometabolism persisted. Our results seem consistent with both models of brain injury suggested in HUS, featuring both mild/symmetric and reversible involvement of gray matter in most patients (metabolic injury) and further focal/asymmetric cortical involvement in patients with relevant neurologic symptoms in acute phase (thrombotic focal vascular damage). Conclusion: Functional brain imaging in acute HUS using F18-FDG PET/CT showed a main pattern (including patients with no neurological signs/symptoms) of significant and diffuse/symmetric impairment of perfusion/metabolism in posterior cortex and cerebellum, with minor impairment in basal ganglia and recovery within some months. Focal/asymmetric pattern of cortical hypoperfusion/hypometabolism in HUS seems associated with more relevant neurological symptoms/signs in acute phase. Introduction. Bone metastatic disease is a complication of prostate cancer. The diagnosis usually relies on skeletal x-ray and bone scintigraphy. The clinical management of bone metastatic disease is difficult, therefore markers of bone remodeling could contribute in diagnosis and follow up of bone metastases. The major structural protein in bone is type I collagen. It is synthesized by osteoblasts and accounts for ~ 90% of the organic matrix. The amino-terminal propeptide of type I procollagen (PINP) represents a marker of early bone formation during osteoblast proliferation. Aim. This study investigates the role of serum amino-terminal propeptide of type I procollagen (PINP) as indicator of response to bone pain palliation treatment with 89 INTRODUCTION: Strontium-89 ( Metastron® ) is a pure beta-emitter selectively absorbed at bone locations with increased osteoblastic activity, used for palliative therapy. The aim of this study was to review the radionuclide therapy using Strontium-89 chloride in the palliation of painful bone metastases in patients with various malignancies. METHODOLOGY: One hundred and two treatments with Strontium-89 chloride were performed in our Institution between 1989. and 2000. We retrospectively analyzed the data of 69 patients (aged 22 to 85 years, middle age 61.2 years ) with painful bone metastases due to prostatic (44.9%), lung (23.1%), breast (10.1%) and other (21.9%) cancers. Forty five patients received single intravenous dose of Strontium-89 chloride activity of 148 MBq and 24 patients multiple (up to 4) doses in the average interval of 3.2 months. Pain relief, consumption of analgesic drugs and improvement of mobility and life quality were used for estimating the effects of therapy (scale 0-5; 0-no effect to 5-excellent effect). Blood counts were taken after three and after six weeks. RESULTS: Palliative therapy using Strontium-89 chloride showed response rate of over 80%. The effect was described as excellent in 19 (27.5%) patients, and as no effect in 10 (14.5%) patients . Bone pain palliation to some degree (mean 3.37) was induced in the remaining 40 patients. The average duration of palliation after first treatment was 3.7 months. Hematological toxities were in generally mild, making repetitive treatment relatively safe. Severe hematological toxicity (thrombocytopenia and pancytopenia) was registered only in two patients. CONCLUSION: administration of Strontium-89 chloride was shown as effective in pain palliation without induction of severe side effects. Better effects would be expected in patients under good clinical conditions and life expectancy over three months. Purpose The evaluation of the effect of bone seeking radiopharmaceuticals has relied mainly on more or less subjective endpoints such as the multidimensional pain model and quality of life questionnaires. In order to obtain more objective endpoints that correlate well with the subjective endpoints in the palliation of pain caused by skeletal metastases specific bone markers were investigated in a clinical phase I study combining 153 Images taken after administration of 153 Sm-EDTMP show a faint or undetectable activity outside the skeleton. For this reason it has been suggested that the contribution to retained dose can be neglected for dosimetric estimate. Aim of this work was to evaluate the tracer behaviour in the bone (B), soft tissues (S) and urine (U) during the first 24 hrs after administration. Methods. Seventy two patients (47 males and 25 females, age 65.5 +/-11.7 yrs) with multiple bone metastases and preserved renal function were studied 5 (t0) , 280 (t1) and 1380 (t2) minutes (median value) after therapeutic administration of 37 MBq/Kg of 153 Sm-EDTMP. Additional 56 pts with the same characteristics were studied at t1 only. The first measurement was acquired immediately following administration and before bladder emptying to obtain the reading corresponding to 100% activity. The further scans were acquired after bladder emptying. Care was taken to accurately reproduce the patient-contour geometry at each time point. Data corrected per decay were calculated employing the Brenner's method to obtain values of cumulative urine excretion (U), soft tissues (S) and bone (B) uptake expressed as percentage of the t0 counts (injected dose INTRODUCTION: Encouraging results are obtained by the use of Sm-153 EDTMP in Multiple Myeloma (MM) patients to achieve pain control, while bortezomib and Sm-153 combination has been proposed to overcome resistance and to minimize non-tumor tissue toxicity among refractory and relapsed MM patients. In a study of ours, we proposed the combined use of Tc-99m MIBI, that reflects myeloma disease activity, and Tc-99m (V) DMSA in the evaluation of the effectiveness of chemotherapy. The aim of our study was to identify the best imaging modalities in order to access MM pts that will benefit from the use of Sm-153, based on the hypothesis that pts with active disease and osteoblastic bone lesions will have the maximum benefit. MATERIALS AND METHODS: Twenty-three pts were included in the study (12 F/11 M, mean age 63.6±14.2). 18/23 pts had received or were under chemotherapy (pretreated) and 5 pts were untreated (newly diagnosed). Tc-99m MIBI, Tc-99m (V) DMSA and bone scintigraphies were obtained on separate days. X-rays exams were also available. RESULTS: Overall, abnormal scintigraphic findings were found in 16 MIBI scans (12/18 pretreated pts and 4/5 untreated pts), in 18 (V) DMSA scans (16/18 and 2/5 pts respectively) and in 20 bone scans (all pretreated and 2/5 untreated pts). Abnormal X-rays, with osteoblastic reaction were diagnosed in 17 pts (all pretreated). The 16 pts with disease activity (MIBI positive scans) had: 13 positive /1 negative (V) DMSA scans, 15 positive / 1 negative bone scans and 10 positive / 6 negative X-rays. Regarding negative MIBI scans, 5/7 were positive in both (V) DMSA and bone scans and 7/7 had positive Xrays. CONCLUSION: MIBI scan can discriminate pts that will benefit from the use of Sm-153 EDTMP; yet, bone scan can be a further inclusion or exclusion criterion rather better than (V) DMSA scintigraphy or X-ray exams.

Assessment of response to systemic metabolic radiotherapy with 153Sm-EDTMP in oncology patients with osseous metastases, as regards to the extent of scintigraphic findings and the sort of primary malignancy. Concerning the performance status were fixed three images: A-PS, B-PS, C-PS, >70%, 50%-70%, <50% respectively, according to Karnofsky index. Three reply types were defined regarding the analgesic outcome: complete relief -drug therapy withdrawal (TI), medium improvement (TII), no response (TIII). Our patiensts were classified into three groups regarding the number of metastases: GI (<5 foci), GII (5-10 foci), GIII (generalized metastatic disease). All parameters were evaluated before treatment, followed up daily for a 4-week period and reconsidered after three months. RESULTS: GI group presented 19 A-PS, 1 B-PS, 1 C-PS images, and 15 TI, 5 TII, 1 TIII reply types. Correspondingly, we had 13-3-9 images, 11-8-6 replies in GII group, and 4-3-14 images, 7-7-7 replies in GIII group. Prostate cancer patients presented 22 A-PS, 3 B-PS, 7 C-PS images, as well 23 TI, 8 TII, 1 TIII replies, while breast cancer patients 11-2-2 images and 8-4-3 replies. In patients suffered from lung cancer (2-0-7 images, 1-4-4 replies) or other malignancies (1-2-8 images, 1-4-6 replies), results weren't encouraging. Flare phenomenon and myelotoxicity weren't remarkable. Palliative impact achieved within the first week and continued during the surveillance time in most cases. Coexistence with EBRT or chemotherapy was generally positive. In contrast, bisphosphonates seem to diminish radionuclide's effectiveness possibly because of similar strong affinity to bone's calcium phosphate. CONCLUSIONS: Samarium therapy in osseous metastatic disease is briefly satisfying, with apparent improvement in life quality. Patients with fewer metastatic lesions, appear to have better answer. Prostate and breast cancer without noticeable variations, had stronger response. Potential combination with other treating options, undeniably creates profits, except bisphosphonates. In this case, we suggest mediating at least a 2-week period. Introduction Radioisotopic synoviectomy is an interesting therapeutic option in inflammatory joint diseases. In patients (pts) with joint function impairment and severe pain due to various benign bone diseases resistant to steroid and no steroid anti-inflammatory drugs, it can improve life quality aging on spontaneous and movement related pain, so that artroprostesis can be delayed with particular benefit in young population. Aim To validate efficacy in pain reduction of benign joint diseases and in delaying time of surgical correction in young patients. Methods 24 pts (age 35-75) enrolled in the study were affected by: rheumatoid arthritis (8 pts), osteo-arthritis (8pts), polyetilene disease (4 pts) and femore necrosis (4 pts). Ankle and knee were the joints communely affected, treated with tradional therapy consisting of systemic steroid or no steroid drugs and intra-articular steroid injection without benefit for the pts. So these conventional therapy resistent pts received intrarticularly administration of Renium 156 (185 MBq) in ankle (16 pts ) and Yttrium 90 (185 MBq) in knee (8 pts). The immobilitation time required after injection was 48 hours for all of them. Pts underwent tree phase bone scintigraphy before and 6 months after therapy and clinical controls after 2 days, 7 days, 3 and 12 months. Results At involved joint tree phase bone scan showed increased vascular and blood-pool phase before radiosynoviortesis and normal scan at post-therapy control. No early collateral effects were observed and no pain was referred by pts during 1year follow-up. No pts underwent to surgical artroprostesis, including pts affected with polyetilene disease and femore necrosis, in which radiosynoviortesis is an unusual approach. Conclusion Radiosynoviortesis can be a valid therapeutic chance in articular pain and function impairement of joints affected with inflammatory diseases and can delay surgical option when needed. So it can be suggested particularly in young population for which delay is a crucial point of therapeutic strategy. Moreover our preliminary results indicate that polyetilene disease and femore necrosis can be succexfully treated as new therapeutic approach. Aim: The radionuclide synovectomy, which is also known as radiosynoviorthesis (RSO), has been used effectively for a long time in the treatment of recurrent hemarthrosis in hemophiliac patients. We report the results of 186-Rhenium radiosynoviorthesis in hemophiliac patients of medium sized joints. Material and methods: Between May 2007 to April 2009 we administered 12 RSO injections in 7 children and 2 adults {mean age: 14.11 ± 9.8 years (min: 9, max: 29)}. The treatment was repeated in one patient and in three patients two joints were treated. 186-Re colloid in 1 cc dosage was used for ankle and elbow joints. The joint was then manipulated through a full range of extension and flexion, to distribute the particules homogeneously throughout the joint space, and splinted for 72 hours to minimize the leakage. All the patients had severe hemophilia A, with grade 2 or grade 3 synovitis. None of the hemophiliac A patients had previously had an inhibitor. Before RSO, patients had mean hemorrhage incidence of 4.4 / monthly, in the last 6 months. Two hours earlier than the treatment all patients began to receive factor prophylaxis and they have continued to receive factor prophylaxis for three days. All the procedures were performed under aseptic conditions. Results: Mean patient follow-up after RSO was 15.7 ± 7.8 months (min:2 max:22). After RSO, patients had mean hemorrhage incidence of 1.8 / monthly. In 5th day of the injection one patient suffered from hemorrhage in his ankle.

Excluding that patient none of the patients encountered any acute or chronic hemorrhage or other complications. Re-injection was planned to decrease synovial volume in a patient with prolonged chronic synovitis. Conclusion: RSO is an effective and promising method for chronic synovitis and recurrent hemorrhage in hemophiliac patients, particularly with frequent intraarticular bleedings. The anti-hemophiliac factor consumption was markedly reduced in patients after RSO therapy. Radiosynoviorthesis is well tolerated by patients suffering from hemophiliac hemarthrosis. Aim Due to its anatomical complexity, knee joint was chosen to study the diagnostic contribution of SPECT-CT in a conventional gammagraphic procedure. The aim of this study was to detect pathological findings in a group of patients suffering benign disorders. Matherials and methods Thirty-five patients (medium age: 57y [19-81y] ) suffering previous traumatism (n=16), knee prosthesis (n=4) or chronic pain (n=15) were included. Bone scintigraphy studies were performed in all patients by means of planar images in different proyections (AP/PA/Lateral) and SPECT-CT. Complementary dynamic exploration was performed to 30 patients. All patients were explored in a hybrid system (SYMBIATruePoint SPECT-CT SIEMENS TM ). SPECT-CT protocol included a fast acquisition SPECT and low-dose CT. Results Triple-phase and planar studies were evaluated and compared with SPECT-CT images. Pathological findings were associated in our series to osteoid osteoma (n=1), loosening prosthesis (n=4), joint inflammation (n=16), insertional disorders (n=4), osteochondritis (n=14) and osteonecrosis (n=1). In 9 of the 35 patients (26%) conventional images contributed to complete a final diagnosis of the process. However, SPECT/CT improved the location of these pathological findings in 26 of the 35 patients (74%). Moreover, fusion images contributed to detect new findings as insertional pathologies, osteochondritis or osteoid osteoma. Conclusion SPECT-CT is an important tool to explore knee joint in benign disorders. According to these preliminary results, insertional lesions and non-suspected osteochondritis focus were considered the principal contribution of this method. Avascular necrosis (AVN) which is also called osteonecrosis or aseptic necrosis, is a condition in which the death of bone cells due to decreased blood flow can lead to pain and collapse of areas of bone. This collapse of bone can lead to degenerative arthritis of nearby joints. Avascular necrosis is most common in the hip joint. Conditions commonly associated with AVN are serious trauma, extended and/or high doses of corticosteroid medications, and excessive alcohol consumption. AVN is suspected most often when a person with risk factors for the condition experiences localized bone-type pain, often felt in the groin. Diagnosis is obtained by radiography of the painful hip. Because early x-rays are usually normal in the early stage of the disease, bone scintigraphy (BS) and MRI are the diagnostic modalities of choice since both can detect minimal changes at early stages of the disease. A variety of methods are now used to treat AVN, and the most common is the total hip replacement. More precise AVN staging can be achived by use of three-phase BS with SPECT. In patients with AVN of the hip three-phase BS with SPECT is significant in early detection and separation of patients with spontaneus healing from those who need surgery.The aim of study was detection and staging of AVN of the hip using three-phase BS with SPECT in patients with suspected AVN. MATERIALS AND METHODS: Three-phase BS and SPECT of the hips were done in 24 patients with suspected AVN. AVN was due to high doses of corticosteroid therapy in 12 pts, due to hip trauma in 6 pts, as a result of SLE in 2 pts, and in 4 pts AVN was idiopathic. In 14 pts AVN was diagnosed by BS, and in 10 pts AVN was diagnosed previously by MRI and confirm by BS. Positive scintigraphic results were classified in three scintigraphic stages: 1-early, 2-intermediate and 3-late stage of AVN. RESULTS: Three-phase BS with SPECT was positive in all patients (100%). In 6 pts (25%), AVN was in early stage. Twelve pts (50%) had intermediate stage, and 6 pts (25%) had late scintigraphic stage of AVN. Twenty pts had unilateral and 4 pts had bilateral AVN of the hip. CONCLUSION: Three-phase bone scintigraphy with SPECT is very sensitive method for AVN detection. Three-phase BS with SPECT can establish stage and prognosis of AVN and influence further therapy.

Quantitative Three Phase Bone Scan and SPECT Studies in Complex Regional Pain Syndrome INTRODUCTION: Complex Regional Pain Syndrome (CRPS) is a chronic progressive disease characterized by severe pain, swelling, vasomotor dysfunction and changes in the skin of the affected limb. We aimed to evaluate the changes in activity accumulation in foot bones besides periarticular areas on Tc-99m MDP TPBS for early diagnosis of cases with posttraumatic lower extremity CRPS type I. MATERIAL&METHOD: 42 cases with lower extremity CRPS type I.and healthy 10 cases (9 M, 1 F) underwent to bilateral foot radiography, Tc-99m TPBS and MDP SPECT. Dynamic and static plantar and lateral scintigraphic images were obtained after IV 740 MBq Tc-99m MDP injection. Following visual evaluation, ROIs were drawn on bilateral foot phalances, metatarsal and tarsal bones, calcaneus and distal tibias. Mean net counts were calculated for all cases. Affected and normal extremity values were compared. RESULTS: 4 cases detected fracture on SPECT images were excluded from study. Mean age was 35 ± 13 yrs for remained 38 patients (29 M, 9 F), 29 ± 3 yrs for control group Direct graphies were normal in all control cases and 29 patients, only 9 patients were osteoporotic. Although counts of affected extremity was not different from normal extremity on first-pass (FP) and blood-pool (BP), significant difference was detected in late static images in CRPS cases ( Aims: Long-term bisphosphonate therapy, especially with the higher doses given intravenously for multiple myeloma or malignancy, is associated with bisphosphonate related osteonecrosis of the jaw (BRONJ). The latter is a diagnostic challenge as clinical exam and plain films (Panorex) can be equivocal. Additionally, treatment is often complicated by overlying osteomyelitis (OM). 99m Tc-MDP bone scintigraphy has been shown to be very sensitive for ON as well as OM, but not specific. The combined metabolic and anatomic information in 18 F-FDG PET/CT may provide a sensitive method to help differentiate and diagnose ON and OM of the jaw, as well as assess treatment response. The utility of 18 F-FDG PET/CT for this indication is evaluated further.

Methods: This is a retrospective study of 13 patients (pts) with ON ± OM of the jaw evaluated with 18 F-FDG PET/CT. The pts included 9 women and 4 men, ranging from 47 to 86 years-old (mean: 72). The average duration of bisphosphonate therapy upon initial presentation was 4.2 ± 2.7 years. In addition to the initial scan, 5 pts also had a follow-up PET/CT after completion of therapy. The PET/CT findings were marked as either positive or negative, and compared to the pts' clinical and histological results. Results: Table 1 summarizes the patient demographic and imaging findings. In all but 1 case (9/10 pts) the pre-therapy PET/CT scan was positive in patients with OM (the majority of whom also had ON). Three of four patients who had negative pretherapy PET/CT scans did not have pathology proven OM, though 2 did have ON. As such, only 1 patient with biopsy proven OM had a negative PET/CT scan initially. After therapy, in all but 1 case (4/5 pts), the PET/CT findings either resolved or improved in comparison to the initial scan. Clinically, all 5 pts improved after therapy. Conclusions: The findings suggest that 18 INTRODUCTION: Low back pain is a common reason for visiting a physician. Imaging strategy varies according to the background of acute or persistent low back pain. The use of lumbar spine radiography and either CT or MRI is well established, whilst bone scan is not included in the diagnostic work-up. However, bone SPECT seems to be a valuable tool in the assessment of inflammatory back pain and in the detection of active sacroilitis. The aim of this study was to evaluate bone SPECT findings in patients referred to our department with mechanical low back pain of recent origin. MATERIALS AND METHODS: Thirty-eight patients (thirty males, eight females, mean age 28 yrs) underwent SPECT of lumbar spine-sacroiliacs. All had pain for less than a month, associated with conditions of physical stress (military or athletic training). None had findings from the x-rays exams. SPECT study was performed 3 hours after IV administration of 20 mCi Tc-99m HDP by a single-head gamma-camera (SPECT data: patient at prone position, 180 o rotation, 32 projections of 60 seconds, matrix 64x64, iterated reconstruction method). RESULTS: Thirty-nine totally lesions were found in 28/38 patients. Bone SPECT revealed findings justifying the pain in 13 patients (pars defects, spondylolysis, fractures, facet joint arthritis, and transitional vertebrae with increased radiopharmaceutical uptake). Fifteen patients had findings that needed further evaluation from the practitioner (vertebrae body stress, enthesopathy of the pelvis and spinous procecess) and 10 patients had no findings at all. The most common lesion detected was stress of the vertebrae body (in 14 patients) followed by pars defect (in 6 patients). CONCLUSION: Bone SPECT imaging revealed the etiology of recent mechanical low back pain in a great percentage of patients and can thus provide useful additional data to the enquiry of pain. Its application on conventional planar bone scan, an economic and widely available diagnostic technique, appears to be a valuable aid for the referring physician. Ankylosing spondylarthritis (AS) is a chronic syndrome associated with the presence of the human leucocyte antigen (HLA)-B27. A 25% of these patients develop serum-negative peripheral arthropathy (SNPA) in which actively inflamed joints coexist with others being in remission. By definition, these patients are serum negative in the antigen associated with rheumatoid arthritis. Compatible bone scan (BS) reveals joints with increased activity due to degenerative alterations, whilst scanning with human polyclonal immunoglobulin (HIG) is capable to show which of the joints present active inflammation of the synovial membrane. The aim of the study is to investigate the utility of molecular imaging with HIG in patients suffering from AS with coexisting SNPA. Sixteen patients suffering from SNPA, with a mean age 35.3+7 years and duration of disease 15.3+4.5 months, who were recruited from a total of 70 patients with AS, are enrolled in the study. All these patients were positive in the human leucocyte antigen (HLA)-B27 and negative in the antigen associated with rheumatoid arthritis. All patients were submitted to xrays and ultrasound examination (US) in joints of interest, plus whole body BS with 99m Tc-MDP and finally scan with 99m Tc-HIG. A total of 640 joints were evaluated. In 4 of the patients (160 joints), molecular imaging with HIG was within normal limits, whilst in compatible bone scan degenerative alterations have been mentioned in 22 of the joints. In all these patients disease was evaluated as inactive. In the remaining 12 patients (480 joints), increased accumulation of HIG was mentioned in 163 joints, whilst BS revealed degenerative changes in 265 joints. Increased uptake of HIG was found in 134/165 swollen and painful joints yielding thus a sensitivity of 81.1%, plus in 29 joints without any clinical evidence of inflammation. Matched findings between these two methods were mentioned in 155 out of 163 joints with an abnormal scan with HIG. Abnormal x-rays and US findings were mentioned in 67 of the joints. According to the above mentioned, BS in SNPA reveals joints being actively inflamed or not, whilst radionuclide study with HIG is the proper one and the method of choice to distinguish actively inflamed joints from inactive ones, presents an acceptable level of sensitivity when compared to clinical appearance of inflamed joints, and finally, it reveals synovial inflammation in a greater extent than anatomical imaging modalities. Background Disease activity of rheumatic conditions is notoriously difficult to monitor with the presently available clinical armamentarium. Active disease is often under appreciated with resultant delays in implementation of therapy. Conversely, the indiscriminate use of therapeutic agents can, and does, result in otherwise preventable morbidity. Aim The aims of this project were to investigate: i) the ability of 99m-technetium-labeled glucosamine ( 99m Tc-ECDG) to localize in joints and other inflamed tissues in patients suffering from Rheumatoid Arthritis (RA) or Systemic Sclerosis (SS), and, ii) whether uptake of this agent correlated with disease activity. Methods Patients suffering from RA or SS, and with varying disease severity, but not taking glucosamine, were recruited to the study. Patients without documented inflammatory disease (with particular emphasis on peripheral joint, lung and muscle involvement) were used as negative controls. All patients were fasted for 4 hours and injected intravenously with 99m Tc-ECDG (600MBq). Planar (spot and whole body) and SPECT scans were acquired at fifteen minutes, two hours and three-four hours post-injection using a Siemens e-Cam gamma camera. Results Thirty patients (18 with RA, 12 with SS) were recruited. Tracer accumulated in joints with clinically active disease, and the degree of uptake correlated with disease activity. Subclinical disease (as determined on follow-up of these patients over the ensuing 6 months) was also detected. No appreciable uptake was seen in joints with quiescent disease. In larger joints sufficient imaging resolution enabled distinction between an inflammatory process involving primarily the synovium and one involving the cartilaginous structures. In patients with SS, 99m Tc-ECDG accumulated only in lungs with active inflammation. Tracer uptake correlated well with pulmonary function tests and was a better discriminator of active disease than computed tomography scans of the lung. Diffusely increased tracer uptake was also noted in the muscles of patients with active myositis. Uptake correlated well with symptoms, and was more sensitive than biochemical markers, such as creatine kinase levels. Conclusion With the development of small animal SPECT/CT and PET/CT scanners it is now possible to have high resolution quantitative data on activity distributions in mice and rats. The pharmacokinetics of a targeted radionuclide therapy agent can now be followed almost in real time and also its pharmacodynamics can be easily studied by giving concomitant drugs to alter e.g. its renal uptake pattern. Ideally the quantitative data should be valuable for estimating the radiation dosimetry of a compound instead of using several animals per time-point as done traditionally. This can reduce not only the number of animals needed but also the total time per experiment considerably. Several aspects of small animal dosimetry based on imaging data will be presented and discussed. Various stylized phantom models for normal sized rats and mice have been developed, that enable "ready made" dose calculations with S-values for source and target organs, using the MIRD formalism 1,2,3,4 . Animal specific dosimetry using the actual anatomy from the CT-data and voxel-based dose models suggest higher accuracy 5 . Determination of the compound's pharmacokinetics, however, may form a more critical parameter than anatomical accuracy. Especially the slower excretion pattern may be problematic to quantify, or would necessitate very high injected activities. The dose by these high activities might cause effects in radiation sensitive organs like the kidneys, thus influencing the normal PK of the compound 6,7

. What can be learned from performing dosimetry in small animals? The kinetic profile of the compound and especially the uptake pattern in organs and tumours is usually the main aim of such studies. Dosimetry can be used to establish dose-effect models for damage in dose-limiting organs and for efficacy in tumor control. Allometric transformation of animal-based dosimetry to human equivalent dosimetry depends on all aspects discussed: not only the difference in the anatomy, but also the dose models for radiation transport, the pharmacokinetics and the dose effect relationships. Targeted radionuclide therapy is a rapidly growing field in nuclear medicine. Previously only radioiodine was available for targeted radionuclide therapy of benign and malignant thyroid diseases. Nowadays there is a number of approved radiopharmaceuticals (e.g. MIBG, phosphonates, anti-CD-20-antibodies). Beside these commercially available radiopharmaceuticals numerous newer compounds are under preclinical and clinical investigation. Radiopeptides are of particular interest for radionuclide therapy as they feature highly suitable pharmacokinetics (rapid targeting, high diffusibility and fast clearance). Most experience was acquired with radiolabeled somatostatin analogues. The somatostatin analogues are exemplary for the development of a radiopharmaceutical with its way from a non radioactive drug to an imaging agent and further to a therapeutic drug. Efforts are made to improve this therapy further as e.g. reduction of toxicity. An overview of the current status and approaches for improvements will be given. A number of other radiopeptides such as gastrin-, bombesin-, and substance P-derivatives are in clinical studies. These studies as well as the specific limitations of these peptides will be discussed. As many radiopeptides are conjugated with DOTA, they could potentially be labelled with an alpha emitting radionuclide. However, the generally short physical half life of the alpha emitters is a drawback. The direct intratumoral application might be a strategy to circumvent this problem. The results of a phase I/II study with 213 Bi-DOTA-Substance P for the intratumoral therapy of malignant glioma will be reported. Antibodies are much larger than peptides and their biodistribution is much slower. However, antibodies are relatively simple to be engineered and can be directed against a selected antigen. Two anti-CD-20 antibodies for the treatment of malignant lymphoma are currently FDA approved and commercially available. However, their clinical acceptance from medical oncologists is still limited. It remains unclear at which time point in the course of the disease radioimmunotherapy should be used. With regard to the most recent studies this question will be addressed. As the most suitable radionuclide is not defined as yet the newly developed 177 Lu labelled antibody 177 Lu-DOTA-Rituximab will be discussed as well.

Certain small radiolabelled molecules such as radiofolates are currently tested in preclinical studies. Selected results will be presented. Additionally specific advantages and drawbacks will be discussed and their pharmacodynamic properties compared with other radiopharmaceuticals for targeted radionuclide therapy. Finally an outlook for the further developments in targeted radionuclide therapy will be given. Background The use of vasodilatory pharmaceuticals is a generally accepted way to assess hyperemic myocardial perfusion using PET and H 2 15 O, but may cause hypotension and pulmonary afterload reduction in patients with pulmonary arterial hypertension (PAH). Assessment of myocardial perfusion during exercise circumvents these adverse effects and reflects a physiological response of the heart to physical activity. Here, we aim to study the feasibility of using a recumbent bike during dynamic PET to induce stress myocardial blood flow (MBF) of both the left and right ventricle in PAH patients. walls (LV and RVFW) were delineated and MBF was computed. Flow reserve was defined as the ratio of MBF during stress to rest. During right heart catheterization performed within a month prior to PET, pulmonary arterial pressure (PAP) was measured at rest and during 40% of maximal cycling load. Heart rate and systemic blood pressure (BP) were monitored during rest and exercise. Rate pressure product (RPP) was calculated as the product of heart rate during PET and systolic BP or PAP. Results Mean MBF of the LVFW at rest was 0.89 (SD±0.14) and increased to 1.41 (±0.40) ml/min/g during exercise (paired t-test p < 0.01); LVFW flow reserve was 1.56 (±0.28); LV RPP was 7859 (SD±1289) and 14000 (±1812) beats-mmHg/min, respectively. Mean RVFW MBF at rest was 0.61 (±0.14) and increased to 1.25 (±0.35) ml/min/g during exercise (paired t-test p < 0.01); RVFW flow reserve was 2.11 (±0.57). RV RPP was 5645 (± 1313) and 11574 (±2546) beats-mmHg/min, respectively. For both LV and RV free walls, there was a positive correlation between MBF and RPP: r=0.50 and r=0.77, respectively. Conclusions Performing submaximal exercise on a recumbent bike during H 2 15 O-PET is feasible to assess hyperemic MBF in PAH patients. MBF in both the LV and RV increased significantly during exercise. Furthermore, there was a positive correlation between MBF and the RPP in both the the LV and RV. N-ammonia and PET/CT in ml/g/min at rest, and during pharmacologic vasodilation with dipyridamole in healthy controls (CON, n=10) and in individuals with cardiovascular risk factors such as arterial hypertension, smoking, diabetes mellitus, hypercholeterolemia and obesity but without CAC (group 1; n=15) or with CAC (group 2, n= 13). MBF was assessed globally as mean MBF, and in the mid and mid-distal myocardium of the left ventricle (LV). A decrease in MBF from mid to middistal LV myocardium was defined as longitudinal MBF gradient. Results: Compared with CON, the global hyperemic MBF progressively declined in group 1 and group 2 (2.10±0.60 vs. 1.65±0.30 and 1.45±0.48 ml/g/min, respectively; p<0.001), while it did not differ significantly between group 1 and group 2. Absolute MBFs during pharmacologic vasodilation were significantly lower in the mid-distal than in the mid LV myocardium in group 1 and group 2 (1.45±0.25 vs 1.78±0.23 ml/g/min, and 1.35±0.47 vs 1.58±0.52 ml/g/min, p<0.0001), resulting in a MBF gradient that was significantly higher in group1 than in group 2 (0.32±0.15 vs. 0.23±0.11 ml/g/min, p<0.0001), not observed in CON (0.006±0.05 ml/g/min, p=NS). Notably, the MBF gradient in group 1-2 correlated significantly with the mid LV MBF during pharmacologic vasodilation (r=0.42, p<0.05), implicating the velocity of coronary blood flow as an important determinant of the MBF gradient. Conclusion: As it was observed, the hyperemic MBF gradient was more pronounced in coronary risk individuals without CAC than in those with CAC, while it dependent the velocity of coronary blood flow. These preliminary results further emphasize functional and/or structural alterations of the epicardial vessel as prevalent cause for the longitudinal MBF gradient. Background: The clearance rate of carbon-11-labeled acetate (11C-acetate) is generally used for the non-invasive assessment of myocardial oxygen consumption with positron emission tomography (PET). Initial myocardial uptake of 11C-acetate, however, is related to myocardial blood flow (MBF). Several tracer kinetic models have been proposed to quantify MBF with 11Cacetate. Our objective was to validate and compare different models for the determination of MBF with 11C-acetate. Methods: Eighteen healthy subjects and 18 patients with hypertrophic cardiomyopathy (HCM) were studied under baseline conditions with 11C-acetate and 15O-water. tumors and exact Rb dose and injection time. Results: Nine scans fulfilled the inclusion criteria. There were five patients with malignant and four patients with benign processes. Rb uptake in all malignant processes was higher than in the benign processes. There was no overlap between the degree of uptake in the malignant and benign processes, suggesting that a cutoff of +2 for malignancy could perhaps be used to distinguish these two types of processes on Rb PET. No formal statistical analysis was performed due to the low number of cases.

Case # Gender Age (y) Size (cm) Uptake Etiology Conclusion: Rb appears to be taken up more avidly by malignant processes than by benign processes and has the potential to be used in cancer imaging. Additionally, incidentally noted increased Rb uptake on cardiac PET CT scan should probably be further evaluated for malignancy. This new area of potential PET utilization warrants further investigation. Our preliminary results represent a first step in that direction. Objectives: Cardiac-resynchronization-therapy (CRT) is increasingly exerted in patients with advanced ischemic coronary artery disease (CAD) and reduced left ventricular function. However, 30-40% of patients do not adequately respond to this costly and time-demanding therapy, even if the implantation surgery was successful and the pacemaker-system is working correctly. The present study aimed to analyse a cohort of CRT non-responders using gated [18F] FDG-PET/CT (PET/CT). We hypothesized, that PET/CT is able to detect possible reasons for the non-response like position of the pacemaker electrodes within areas of non-viable myocardium or persistent left-ventricular dyssynchrony. Methods: Non-response to CRT was defined as the combination of unchanged clinical conditions (same NYHA stage and/or ongoing chestpain) and a minimum of two out of three unchanged clinical parameters consisting of LVEF improvement < 5%, decrease of Brain Natriuretic Peptide (BNP) < 10% and decrease of Left Ventricular End Diastolic Diameter (LVEDD) < 10%). Six patients (5m, 1f; mean age 61±10.1 years) met these criertia and underwent PET/CT 30±19months after CRT implantation. CT display of the pacemaker electrodes was fused with the PET scar map three dimensionally and left ventricular wall motion and synchrony was analyzed. Results: LVEF, BNP and LVEDD in the six non-responders were 27±9 %, 427±99 pg/ml and 71±1mm before and 28±6 %, 324±172 pg/ml and 67±5mm after CRT. All patients got optimized medical treatment according to german guidelines. In 4/6 Patients the lateral pacemaker electrode was assigned to an area with significant reduced myocardial glucose metabolism and reduced wall thickening. Additionally, persistent septal/lateral dyssynchrony of more than 300 ms was found in 3/6 patients. Conclusions: In 4 of 6 patients with unsatisfactory response to CRT implantation 3D-fusion of PET and CT images identified allocation of the pacemaker electrodes within non-viable myocardial areas. These results supporting the theory, that pre-existing myocardial scars could worsen the transfer of pacemaker signals and therefore diminish the grade of resynchronisation leading to persisting clinical discomfort. This hybrid diagnostical approach should be evaluated in a lager cohort of patients before CRT implantation to optimize therapy results by locating the optimal coronary vein for electrode positioning. Introduction Radiotherapy has an important role in cancer treatment. Mediastinal radiotherapy is commonly performed for lymphomas, lung, breast and esophagus carcinomas. Radiotherapy zones can involve some regions of myocardium within the irradiation of mediastinal structures. Since 18F-FDG PET/CT is a noninvasive examination for the diagnosis and follow up of these malignancies, we aimed to evaluate the risk of myocardial damage by observing the biological distribution of FDG in patients who has undergone mediastinal radiotherapy. Materials and Methods The list of the patients who has undergone 18F-FDG PET/CT examination in our hospital, and the list of the patients who has undergone mediastinal radiotherapy were matched. 18F-FDG PET/CT examination was performed in 38 patients at least four months after the completion of radiotherapy. ROI's were drawn over the irradiated and nonirradiated myocardial regions on the PET/CT images. In the database check, it was found that eight of these patients have also undergone myocardial perfusion scintigraphy, and visual analysis of these images was performed. Results In the visual analysis, five patients had diffuse myocardial 18F-FDG uptake (13%), five patients had no significant 18F-FDG uptake (13%) and 28 patients had regional 18F-FDG uptake (74%). The SUV calculations of these 28 patients were significantly higher in the irradiated regions in comparison to other myocardial regions (p<0.001). Six of the eight patients that has undergone myocardial perfusion scintigraphy showed fixed hypoperfusion in the irradiated myocardial regions in consistent with the regions that increased 18F-FDG PET/CT uptake was seen. There was no correlation between the radiotherapy doses and the SUV measurements in the myocardial regions. Conclusion Since the patients had no myocardial infarction or diabetes and these myocardial regions were not consistent with the vascular territory of coronary arteries, the findings might were thought to indicate radiation induced myocardial damage. The patients with mediastinal radiotherapy history that showed increased 18F-FDG uptake, especially in the basal myocardium, should be followed cautiously for the early diagnosis and treatment of cardiac events. Introduction: The development of radioimmunoconjugates as diagnostic tools, which enable the acquisition of important data on tumor localization, is an exciting area of research. Bevacizumab (Avastin®, Roche) is a humanized monoclonal antibody which binds all VEGF-A isoforms. In recent studies it has been shown that radiolabeled bevacizumab accumulates in VEGF-expressing tumors with high specificity. Our efforts are focused on targeting VEGF-A with Bevacizumabconjugated Ferromagnetic Nanoparticles (bc-FNs), thus leading to a highly-specific targeted contrast agent that could be utilized in Magnetic Resonance Imaging (MRI) applications. Materials and Methods: Magnetite Fe 3 O 4 was employed as the FN constituent mainly due to its almost ideal biocompatibility. DMSA was used as the conjugation moiety for the targeting ligand since it forms a stable coating on the Fe 3 O 4 FNs, while its remaining free thiol groups are used for the attachment of the target-specific antibody. The DMSA-FNs were conjugated to bevacizumab, which was adequately modified by use of either sulfo-SMCC, SATA or 2-mercaptoethanol. Conjugation between the FNs and the targeting antibody was proven by means of UV-vis spectrophotometry. In addition, the modification of the magnetic properties of the formed Bc-FNs was investigated by means of a Superconducting Quantum Interference Device (SQUID) magnetometer. Finally, the binding efficiency of Bc-FNs was investigated by means of standard immunostaining tests with FITC-goat anti-human IgG in MDA MB231 human breast cancer cells, as well as in their VEGF-165 transfectants M165, since the former has a moderate expression of VEGF, while the latter overexpresses the cell-associated 165 isoform of VEGF. Results: UV-vis data for the supernatant of the Fe 3 O 4 -bevacizumab conjugates showed no indication of the characteristic absorption of the antibody at 280 nm, indicating the absence of bevacizumab in the supernatant. Immunostaining test with FITC-goat anti-human IgG revealed no green fluorescence activity from cells treated with a control conjugate, but bright green fluorescence from cells treated with the FN-bevacizumab conjugate. Furthermore, a notable difference in fluorescence activity was observed in the two cell lines with different VEGF expression levels. Conclusions: Our results give strong evidence for the efficient formation of Bc-FNs that (i) retain good magnetic properties, (ii) possess high binding affinity and, (iii) good specificity to relevant cancer cell lines. Since the Bc-FNs examined in this work fulfill these three cornerstone prerequisites that should be met for the effective utilization of any contrast agent in MRI we believe that the need of further in vitro and in vivo investigations is fairly documented. PET imaging was carried out over a 6 month period following the AAV administration in treated and control animals with 1-5 MBq of 68Ga-DOTATATE using a clinical PET scanner. Images were acquired 15-20 min after injection and region of interest analysis was utilized to determine SUV values for the tracer in different tissues. IV AAV-TBG-SSTR2 transduced animals showed markedly increased uptake in the liver,that was several-fold above control levels. IM AAV-CMV-SSTR2 transduced animals showed a 3 to 4 fold increase in muscle uptake compared to controls. In both instances, the increase in 68Ga-DOTATATE uptake was dependent on the amount of administered AAV. Liver transduced animals showed a tendency for a decrease in liver uptake over time whereas transduction in muscle showed a steady increased uptake over the 6 month observation period.

Inhaled AAV-CMV-SSTR2 did not yield significant increase in 68Ga-DOTATATE uptake in the lungs. The figure below shows images obtained 1 month after transduction. Panel A shows a control mouse who received intramuscular (IM) and intravenous (IV) control AAV. Uptake is seen mainly in the kidneys and the bladder (route of excretion). Panel B shows remarkable liver uptake of the tracer in a mouse treated with IV AAV-TBG-SSTR2. Panel C shows specific increased uptake of tracer in the thigh of a mouse treated with IM AAV-CMV-SSTR2. Use of the SSTR2 as reporter gene and repetitive imaging with 68Ga-DOTATATE demonstrates that monitoring is feasible and high uptake levels are maintained for long periods of time. This approach may be useful for quantitative monitoring of gene therapy in animal models. (1 to 5% ), 2+ (6 to 9%) to 3+ (>10% positive cells) and for cNIS from 0 (no cell stained), 1+ (1 to 10% positive), 2+ (10 to 30%) to 3+ (30% and more positive) Results: mNIS (1+ to 3+) as well as cNIS stainings were more frequently observed in HR-negative BC (45% mNIS and 67% cNIS) than in HR-positive ones (7% mNIS and 20% cNIS) (both P < 0.01). However, no difference between HR+ and HR/-/ could be detected in the percentage of cells cNIS stained (median : 30% versus 20%, P=0.93). On the another hand, half of the patients scored cNIS 3+ (9/18) had 50 to 80% of the cells stained. cNIS staining was present in 24 out of the 25 cases with mNIS staining. In 22 of the 49 HR/-/ cases classified as mNIS positive, on average only 9% of the cells were stained. However, 4 (31%) of the 13 patients scored mNIS 3+ had 20 to 30% of the cells stained. Results obtained on BC over expressing HER2/Neu suggest that NIS expression is rather related to ER negativity (6 NIS positive out of eight Neu+) than to ER positivity (one out of eight Neu+). No statistically significant difference in rate of NIS staining between Neu amplified and Neu non amplified tumors was found. Conclusions: Our results demonstrate that NIS is more frequently expressed in ER-negative BC than in ER-positive ones. It could make these aggressive ER negative BC the group to be targeted with iodine therapy after the demonstration of their NIS expression and of the in vivo functionality of the symporter. Aim: Whereas somatostatin receptor scintigraphy has been proven a valuable tool for staging endocrine tumors, its sensitivity and accuracy in other cancers, such as metastatic medullary thyroid cancer (MTC) or small cell lung cancer (SCLC), is limited by the poor and inconstant expression of these receptors. The cholecystokinin (CCK)/gastrin receptor (CCK2R) is overexpressed in up to 90% of MTC and 60% of SCLC but not in the corresponding healthy tissues. The CCK2R represents a ideal target for the diagnosis and internal radiotherapy of these tumors. Although previously studies had demonstrated the feasibility of radiolabeled CCK/gastrin ligands to target MTC in animals and patients, different adverse effects were reported indicating that tumor uptake, biodistribution and renal toxicity must be improved for clinical application. The aim of this study was to synthesize and assess the effectiveness of new radioligands with optimized properties to target the CCK2R. Materials and Methods: We have used a tridimensional molecular model of the CCK2R occupied by CCK that we have previously built to design "in silico" modified CCK derivatives covalently coupled to a chelating agent. Two original CCK derivatives have been synthesized, coupled to chelating agent DTPA and to an original chelating multimodality imaging agent before labelling with 111 Indium. The stability and affinity of these CCK derivatives were studied in vitro. Nude mice, bearing NIH-3T3 tumors expressing a constitutively active mutant of the CCK2R, were intravenously injected with these radiolabelled CCK derivatives. In vivo scintigraphy was performed 24 h post injection and compared with the control 111 In-DTPA-CCK8 previously used in the published studies. A dynamic acquisition of planar images was performed. Images analysis was done on a Xeleris workstation. Thereafter biodistribution studies (% ID/g tissue) were done. Results: The conditions of radiolabeling were optimalised to lead to a radiochemical purity > 95%. In vitro studies confirmed that the two CCK compounds displayed nanomolar affinities for the CCK2R and greater stabilities. Scintigraphic and biodistribution studies showed significant improvement of tumor targeting and renal toxicity compared to the control 111 In-DTPA-CCK8: in particular, for the 111 In-multi-modality chelator-CCK derivative, we have a 4-fold higher tumor uptake with a tumor to kidneys ratio higher than 7. Conclusion: A more suitable biodistribution and less renal fixation were obtained for these two new radioligands. In particular, the original multi-modality radiolabeled CCK derivative appears to be a promising candidate for molecular imaging and internal radiotherapy for tumors overexpressing the CCK2R. Aim: In clinical routine, the early determination of response of colorectal cancer (CC) to neoadjuvant radio-chemotherapy is highly relevant. In most of colorectal tumors CEA is expressed. Pretargeting systems allow radioimmuno-mediated SPET and PET investigations. Both techniques are based on the high affinity of antibodies to tumors and the quick kinetics of radiolabelled peptides. TF2 is a humanized bispecific trivalent monoclonal antibody (mAb). This mAb is directed against CEA expressed by tumors and, additionally, to the sequence histaminesuccinyl-glycine (HSG). The HSG peptide IMP288 is DOTA-linked and should bind to TF2 with high affinity. The aim of our study was to investigate the kinetics of the pretargeting system in vitro, the influence of CEA expression levels as well as changes in uptake after external irradiation in vitro prior to patient investigations. h of preincubation with "cold" mAb showed an uptake of 111 In-IMP as high as the radiolabelled antibody, but more rapid kinetics. An external irradiation increased the specific uptake of 131 I-mAb as well as of 111 In-peptide after preincubation with "cold" mAb significantly up to 4-fold (p<0.05), dose-dependently. Conclusions: The investigated pretargeting system allows not only to analyze semi-quantitatively CEA expression of colorectal cancer cells but also to evaluate changes of antibody uptake after external irradiation. In clinical studies the early increased uptake after irradiation has to be considered. The molecular biology basis of these findings is under further investigation.

Imaging of EGFR expression in murine xenografts using sitespecifically labelled anti-EGFR biodistribution of radiolabeled Affibody molecules after injection of different tracer amount was compared in mice bearing EGFR-expressing A431 xenografts. Results. The conjugate accumulated specifically in xenografts and in EGFR-expressing tissues. Injection of small amount of tracer (high specific radioactivity) resulted in uptake in normal EGFR-expressing organs (e.g. liver and salivary glands) and provided suboptimal tumour-to-organ ratios. Increasing the amount of injected tracer up to 50 µg (ca. 7 nmol) saturated EGFR in healthy tissues, but not in xenografts. Further increase of the injected amount resulted in decreased tumour uptake. In murine xenografts, the optimal tumour to organ ratios were obtained after injection of 30-50 µg 111 In-DOTA-Z EGFR:2377 .

The results of the biodistribution study were confirmed by γ-camera imaging. Objective Antisense imaging is one of the important modalities in the domain of molecular nuclear medicine. The purpose of this study was to design, synthesize antisense oligonucleotide molecular probe of human telomerase reverse transcriptase (hTERT) mRNA, and validate the potential application value using animal model experimental study to early diagnose the tumor. Methods Antisense and sense molecular probes targeting hTERT mRNA were radiolabeled with technetium-99m through bifunctional chelator N-hydroxysuccinimidyl derivative of Sacetylmercaptoacetyltriglycine (S-Acetyl NHS-MAG 3 ). The BALB/c nu/nu nude mice were inoculated with MCF-7 mammary tumor cells in the right upper limbs. which are focal or diffuse uptake above background incompatible with normal anatomy or physiology. A defined exception is mild and diffusely increased FDG uptake in residual masses >2 cm, with intensity lower than or equal to that of mediastinal blood pool structures. Results: There was six true and four false positive results in our material by visual assessment alone. All FP lesions had no doubt uptake higher than surrounding background or mediastinal blood pool, but the lesions were small (largest CT-diameter 9, 11, 12 and 26 mm respectively), and with comparatively low SUVs (2,6, 2,8, 2,8 and 3,6). One lesion was mediastinal, one abdominal and two peripheral. The reproducibility of SUV determinations was high. The mediastinal blood pool background varied between SUVmax 2,1-3,6, probably due to individual variations in blood concentration of given x-ray contrast agent affecting the attenuation correction. Conclusion: Using the standard criteria and visual analysis alone there was a 10% FP rate in our material. Our preliminary data indicate that the number of FP residual lymphoma would be significantly reduced using a SUVmax around 3,0 as cut-off in addition to the visual assessment in the post treatment evaluation of B-lymphoma patients Objectives: The aim of this study was to evaluate the predictive value of sequential PET before and after HDT and ASCT in Hodgkin (HL) and Non Hodgkin lymphoma (NHL). Methods: We studied 20 lymphoma patients,9 patients with NHL and 11 patients with HL. There were 10 male and 10 female patients aged between 12 and 65 years (mean 34.58). A pretreatment PET/CT was performed for all patients (PET0, CT0). Follow-up scans were performed on 30th (PET1, CT1), 60th (PET2, T2), 100th days (PET3, CT3). The mean follow-up period was 12 months (range 6-18 months). PET and CT scans were retrospectively blindly evaluated by a nuclear medicine and radiology physicians. Results: PET and CT scans were positive for all patients before HDT/ASCT. PET1 and PET2 scans were positive for 8 patients, PET3 scans were positive for 6 patients. 30th, 60th and 100th day CT scans were positive for 10, 8 and 5 patients, respectively. At the end of 1st year 4 patients died whose PET scans were positive. 12 patients of 20 had negative PET scans confirming CR while 8 patients had negative CT scans. Six patients had still positive CT scans. Two of these 6 patients had positive scan and relapsed. After one year, overall survival and progression free survivals were 100% and 91%, respectively. All results were correlated with clinics and follow up. Conclusions: Our study suggested PET had a higher prognostic value than CT in refractory lymphoma and should be performed as a more valid alternative for posttreatment evaluation. Determination of response in multiple myeloma (MM) is challenging and requires uniform criteria. The response criteria recommended are primarily derived from the International Myeloma Working Group (IMWG). Early evaluation of response with FDG-PET/CT (PET/CT) may be used as a response surrogate in MM and it may improve the response classification. Our objective was to correlate PET/CT findings obtained early after treatment with progression free survival (PFS) and the IMWG response criteria in MM patients who are undergoing therapy after relapse. Methods: Seventeen patients with relapsing MM had a whole body PET/CT imaging 2-3 months after initiation of therapy. Therapy consisted of various combination treatments, mainly based on dexamethasone with thalidomide or equivalent regimens. All patients had a 12-month follow up. PET/CT was evaluated using liver as the reference organ. The laboratory data involving serum and urine M component using immunofixation, serum free light assay and bone marrow biopsy were available in all patients to determine response by IMWG criteria. The therapy response based on PET/CT and IMWG was correlated with PFS at 12 months. Results: Of 17 patients, PFS was not reached in 9 (53%) patients at 12 months while 8 (47%) patients relapsed with a median PFS of 9 months. By IMWG, 7 (41%) patients had CR, 6 had PR, 1 had very good partial response (VGPR), 3 had no response. The patient with VGPR was lumped with the CR group. By PET/CT, 11 (65%) patients had CR and 6 (35%) patients had no response. There were 2 false negative PET/CT studies when IMWG results were true positive. There was no false positive PET/CT results. There were 4 false positive IMWG results when PET/CT was true negative in all. There were 3 false negative IMWG results when PET/CT was true positive in all. The sensitivity, specificity, positive (PPV) and negative predictive values (NPV) for PET/CT and IMWG to predict 12-month PFS were 75%, 100%, 100%, 82% and 100%, 55.5%, 67%, 100%, respectively. Conclusion: In the prediction of 12-month PFS, PET/CT obtained at 2-3 months after therapy appears to have a superior specificity and PPV while IMWG criteria yield higher sensitivity and NPV. The combination of these two methods may increase the accuracy of response classification. Although these data are limited by sample size and short follow up period, these results lay groundwork for further studies to determine the predictive value of PET/CT as a response surrogate. Tc-pertechnetate "cold" thyroid nodule cytologically diagnosed as non-oncocytic (36/51) and oncocytic (15/51) follicular neoplasm. Static images of the neck were acquired at 10 minutes (early image) and 120 minutes (late image) after intravenous injection of 400 MBq of 99m Tc-sestaMIBI. Images were visually assessed using a scoring system: pattern 0 -no increased nodular uptake in both early and delayed images; pattern 1 -increased nodular uptake in early image without retention in the delayed image; pattern 2 -increased nodular uptake in early images with retention in the delayed image; pattern 3 -no increased uptake of the nodule in the early image and increased uptake in the delayed image. For the semiquantitative analysis, regions of interest (ROI) were drawn in 99m Tc-pertechnetate image in correspondence of the "cold" nodule and transferred on the early and delayed MIBI images. A ROI in the MIBI background was also drawn. Then, early ratio (ER) and delayed ratio (DR) were calculated and the retention index (RI) was then found using the formula: RI=(DR-ER)*100/ER. Histological diagnoses of the nodules were used as gold standard. Results . The table reports Conclusions. In summary, our findings indicate that 99mTc MIBI scintigraphy is an effective diagnostic method in patients with non-oncocytic thyroid lesions, improving the accuracy of the conventional cytology if properly selected by FNAB cytomorphology, and allowing a better selection of patients requiring surgery. Semiquantitative 99mTc-MIBI scan resulted to be more sensitive and specific than the visual one for this purpose. Aim Thyroid carcinoma detection is mostly performed on Na-I SPECT/CT image pairs, although the perfect localization is often very difficult due to the poor details of Na-I images. In questionable cases an MDP bone SPECT is acquired to decide if the carcinoma is in the bones or outside of other tissue. Our goal was to automatically perform a triple fusion of the separately acquired MDP SPECT to its corresponding Na-I SPECT/CT image pairs based on our higher dimensional mutual information based registration method. Materials and methods. 34 Na-I SPECT/CT and MDP SPECT image triples were collected. Since the Na-I image had poor details, it was excluded from the registration step. In order to gain a third image, the CT was copied and post processed. A master MDP SPECT representing a normal stage of the bones was chosen. Both actual MDP SPECT and the copy of the CT were normalized by histogram matching to the master MDP SPECT. This way the bone segmentation of the CT could be gained and the anatomical information of the MDP SPECT could be increased. Registration of the MDP SPECT to the CT and the segmented bone CT was performed by a higher dimensional normalized mutual information similarity measurement. For comparison the widely used dual NMI -and four extended MI similarity measurements were performed to superimpose the image triples. After superimposing the MDP SPECT, it was fused with the Na-I SPECT and the CT image in a triple fusion window. Validation of the registration was done by a medical physician based on the triple fusion. The modification of the automated transformation parameters as well as the number of iterations to converge to the optimum was recorded for all similarity measurements. Results Our extended NMI similarity measurement has provided the best registration parameters to superimpose the image triples ( approx. 1mm mean registration error ) and it needed the least iterations to converge to the optimum. Previously proposed extended measurements generated high misalignments in axial directions that were associated with high voxel sizes in the CT images. Triple fusion of the images significantly increased the localization accuracy of the thyroid carcinoma. Conclusion We have presented a method to superimpose thyroid Na-I SPECT/MDP SPECT/CT images. Our future work will focus on the evaluation of the usefulness of our triple fusion visualization environment. Comparisons with the classic dual fusion environment will be performed. Aim: Papillary thyroid carcinoma (PTC) is the most frequent endocrine cancer and it is the most common thyroid cancer (85-95%). Multiple potential risk factors for the incidence of the PTC include radiation exposure, iodine deficiency, and family history. The association between PTC and chronic lymphocytic thyroiditis (CLT) has been reported too. The aim of study was to examine this association leading to neoplastic aggressiveness shift at risk cohort of ethnic Germans from Nord Kasakhstan after possible radiation exposure. Methods: We prospectively studied 42 first-grade relatives (f30; m12; 59 +/-14 y.o.) of patiets with CLT/PTC (Gr.A) and 21 pts with PTC without CLT (Gr.B). 41 of 42 studied patients from Gr.A (99%) were residents of North-Eastern Kazakhstan near to NuclearTestingGround, prior to their repatriation to Germany. Initial investigation included clinical examination, thyroid sonography/99mTc-scitigraphy, thyroid hormone (fT4, fT3, TSH) and anti-TPO/anti-Tg antibodies levels estimation, FNAC. Every case of PTC was confirmed by patho-histological examination. Age, sex, tumour features (dimensions, angioinvasion, capsular infiltration, multifocality and lymphnode metastases, nuclear medicine examination data and therapy history, geographic anamnesis) were analysed. Results: Statistically significant difference in tumour size was founded in two Groups: the average diameter was found to be 1.721+/-0.5812 and 1.145+/-0.871 cm in Gr.A and in Gr.B, respectively (P=0.001). Capsular infiltration was present only in Gr.A in 3 cases. The angioinvasion was found in 8 cases of Gr.A and 1 cases in Gr.B (P=0.310). Multifocality was found in 19 patients in Gr.A and in 2 in Gr.B (P=0.0009). There were no statistical differences in sex (P=0.423) and age (P=0.330). All pts in Gr.A had CLT with high levels of thyroid Abs (TgAb/TPOAb). 17 of 33 (51.5%) autoantibody positive pts with US suspicious multifocal non-uniform thyroid goiter revealed scintigraphic cold lesion, in Gr.B 60% nodes were undetectable in scans. Conclusions Statistically proven high prevalence (100%) of CLT and multifocal PTC in Gr.A compared to Gr.B in our study might be related to the fact, that a majority of pts were previously residents of North-Eastern regions of Kazakhstan (probability of extensive radiation exposure). Indeed, there is a high incidence of CLT/PTC in the regions, adjacent to Semipalatinsk NuclearTestingGround. The external radiation, concomitant HT must be taken into account and assume more aggressive tumours. Our results justify a neccessity of screening for PTC in this population group. A more significant attention of the clinical examination, US guided FNAC and thyroid scan, Doppler will guarantee a precise diagnosis. Purpose: The aim of this study was to evaluate the diagnostic relevance of diagnostic whole body scan(DxWBS) for management of patients with differentiated thyroid cancer(DTC). Subjects and methods: The study subjects consisted of 93 patients (M/F 20/73, mean age; 47yr) who had a high-dose radioiodine therapy after total thyroidectomy for DTC. DxWBS, serum Tg and neck USG were all performed within 2 months. Serum Tg≥2ng/mL(off) or Tg≥1ng/mL(on) and abnormal focal uptake of DxWBS were considered positive. Results: DxWBS was positive in 25(26.9%), serum Tg in 71(76.3%), and neck US in 68(73.1%) patients. DxWBS did not detect lesions but neck USG & serum Tg was positive in 39(41.9%) patients, neck USG did not detect but DxWBS & serum Tg was positive in 10(10.8%) patients, serum Tg was negative but neck DxWBS & neck USG was positive in 2(2.2%) patients. 10 patients(10.8%) were positive for all of DxWBS, serum Tg and neck USG. DxWBS was only positive in 3 patients, while Tg and neck USG were negative. 2 patients had lung metastasis and 1 patient remnant thyroid tissue. In comparison, serum Tg or neck USG was positive in 90 patients(96.8%). Conclusion: The result of our study suggest serum thyroglobulin combined with neck ultrasonography could detect most recurrence or metastatic lesions in patients with DTC. DxWBS does not seem to be efficient method in the detection of recurrence or metastatic lesion in DTC patients.

Objective: To assess the additional value of SPECT-CT scanning over planar imaging and ultrasound only for the detection of cervical lymph node metastases around I-131 ablation. Methods: A planar whole-body imaging study with detailed images of the cervical region was acquired and a SPECT-low-dose-CT scan was recorded from the mandibula to below the sternoclavicular joints in 55 patients. Results: Overall, 27/55 (49%) patients were judged to be negative for the presence of cervical lymph node metastases, 22/55 (40%) positive and 6 patients (11%) indeterminate for the presence of lymph node metastases based on planar imaging. After SPECT-CT imaging these numbers were 35/55 (64%), 20/55 (36%) and 0/55, respectively. 4 patients who were negative on planar imaging were positive SPECT-CT, and positive 6 patients were negative in SPECT-CT. In all, SPECT-CT was of clinical benefit in 27/55 (49%) patients. In ultrasound 19 patients showed enlarged lymph nodes on ultrasound of the neck; in only one of these patients the enlarged lymph nodes were classified as likely to be malignant. Only 7 of these patients showed lymph node metastases on SPECT-CT, additionally 9 other patients that did not show enlarged lymph nodes on ultrasound were found to have cervical lymph node metastases by SPECT-CT. Conclusion: SPECT-CT allows a greater rate of detection of lymph node metastasis, more precise determination of lesion dignity as well as more precise localisation of lymph node metastases than planar imaging and / or ultrasound. It is of clinical benefit in half the patients undergoing ablation. Objectives: To document anato-functional patho-physiological 131 I uptake patterns with SPECT/CT in differentiated thyroid cancer (DTC). Methods: We reviewed 29 cases of DTC patients from the Canadian thyroid cancer database who underwent a planar whole-body scan (PWB) followed by a SPECT/CT study after administration of a diagnostic (n=5) or a therapeutic (n=24) 131 I dose. DTC patients were imaged on an integrated SPECT/low-dose CT scanner (Infinia™ Hawkeye™ -1/-4, GE Healthcare). SPECT/CT data were compared to PWB, and correlated to clinical data, Tg levels, high-resolution neck US, diagnostic CT, brain MRI, barium swallow oesophagus, dacryoscintigraphy, 18 FDG PET/CT, and pathological results. Results: Following the PWB, SPECT/CT allowed definition of various patho-physiological 131 I uptake patterns: 1) physiological patterns in the neck corresponding to the lacrimal sac, naso-lacrimal duct, nasal fossa, oro-pharynx, parotid glands, sub-mandibular glands, thyroglossal tract, thyroid bed, scalp and hair contamination; 2) physiological patterns in the thorax corresponding to the thymus, oesophagus, stomach, and breasts; 3) physiological patterns in the abdomen corresponding to the transverse colon, ascending and descending colon; 4) physiological patterns in the pelvis corresponding to the uterus, sigmoid colon and rectum, the bladder, and urinary contamination; 5) pathological patterns corresponding to DTC metastases were precisely localized in the brain, lungs, liver, the skeleton, and lymph nodes; 6) pathological patterns related to benign diseases including dental work, lacrimal duct obstruction, mastoiditis, an atypical mycobacterium lung tuberculosis, an ovarian teratoma with struma ovarii, a breast cystic mass, a salivary gland cyst, a gastro-oesophageal reflux, and a diaphragmatic hernia; Conclusions: In DTC patients, SPECT/lowdose CT allowed clarification of equivocal planar 131 I-WBS for better anato-functional definition of patho-physiological uptake patterns. Aim: The introduction of SPECT/CT into clinical routine reveals new diagnostic aspects in detecting the exact morphologic analogue of increased tracer uptake in different scintigraphic findings. Considering patients under I-131 surveillance or primary detection of unkown metastases in I-131 ablation, the question arises to what extent SPECT/CT improves the interpretation of diagnostic scans. Materials and Methods: 28 SPECT/CT examinations were performed in 25 patients (13 men and 12 women, aged 18 -83 years) suffering from malignant thyroid diseases (11 papillary cancers, 8 follicular cancers, 1 both papillary and follicular cancer, 1 mixed medullary and papillary cancer, 2 occult thyroid cancers (1 Graves' disease with previously unknown lung metastases, 1 multifocal autonomous thyroid disease (MFA) with a previously unknown focal bone metastasis). Two patients had ectopic thyroid parenchyma according to pathological findings in I-131 whole body scans. Anterior and posterior images as well as spot views of the neck were performed 72 hours after oral application of 0,4 -6,0 GBq I-131; a dualheaded whole-body ECAM camera (Siemens, Germany) was used : high energy collimator, scan time 10 cm/min, 256x1024 matrix, zoom 1. SPECT/CT followed using a Symbia dual-headed whole-body gamma camera (Siemens, Germany): SPECT 128x128 matrix, zoom 1, rotation 180° and 36 steps/head, scan time mainly 40 sec/view. Subsequently a low dose CT in the same acquisition position was carried out. An iterative SPECT reconstruction was applied as well as a CT recontruction for bone and soft tissue. Results: Planar scintigraphy showed 50 tumour suspicious foci with increased I-131 uptake but SPECT even 57 foci whereas CT presented 55 foci with a corresponding morphological structure. In 17 patients (46 foci) tumour recurrence or metastases were detected in this way. In 6 patients (9 foci) metastases could be excluded. In 2 patients (2 foci) CT demonstrated no morphological analogy. In comparison to planar scintigraphy the additive use of SPECT-CT considerably increased the sensitivity and illustrated the corresponding morphological structures. In this context it should be kept in mind that image fusion of I-131 SPECT with CT or NMR (acquired before or after I-131 scan) is difficult due to the absence of special landmarks for precise fusion and due to obstacles during reproducible patient positioning. Conclusion: I-131 SPECT/CT in patients with thyroid cancer offers an improved tumour localisation involving a higher diagnostic sensitivity. Aim: To find optimum reconstruction parameters for I-131 post therapy SPECT and assess the use of resolution recovery in the context of acquired counts. Materials and methods: Preliminary assessment was based on 15 parameters applied to phantom data, for objective and subjective analysis. Three parameters were discarded and remaining applied to two patient datasets for qualitative evaluation by two clinicians. Data analysis narrowed these parameters to six, two Filtered Backprojection (FBP) and four Astonish (Ast): 

3D dosimetry with standard and voxel MIRD methods on Intraoperative Avidinination for Radionuclide Therapy (IART ® ) to evaluate absorbed dose and radiobiological effects A. Di Dia 1 , F. Botta 1 , M. Ferrari 1 , A. Sarnelli 2 , M. Cremonesi 1 , C. De Cicco 1 , G. Pedroli 1 , G. Paganelli 1 ; 1 European Institute of Oncology, Milano, ITALY, 2 IRST, Istituto scientifico Romagnolo per la cura e lo Studio dei Tumori, Meldola, ITALY.

The new procedure named IART ® has been applied in early breast cancer patients immediately after surgery to irradiate the residual mammary gland. This approach consists of tumour bed targeting using the avidin-biotin system. The therapeutical rationale was to deliverimmediately after surgery, by the injection of 90 Y-biotin-a Biologically Effective Dose(BED) of 21

Gy as a boost anticipating external beam radiotherapy(EBRT). The aim of this study was to compare dosimetric evaluations derived from standard (MIRD 16) vs. voxel (MIRD 17) methods. The BED and Equivalent Uniform biological effective Dose (EUD) were evaluated in order to assess the possible effect, including dose distribution heterogeneity. Methods: Fifteen patients were evaluated. The tumour bed was avidinated (100 mg) during surgery, after tumour removal, and targeted by systemic injection of 3.7 GBq of 90 Y-biotin (+ 111 In-biotin,185 MBq, for imaging) one day later. The therapeutical target was considered to be the region in which the uptake was >50% of the maximum in the breast. Average self-dose in the target was calculated with standard MIRD method, assuming spherical shape and deriving patient-specific biokinetic data from sequential images (planar+SPECT). For voxel dose calculation, a dedicated software was developed (Matlab ® support, Mathworks). Input data were: SPECT images (activity distribution), biokinetic data (planar images) and S-voxel factors for 90 Y and 4.4 mm voxels, specifically calculated for by Monte Carlo simulation (PENELOPE code). BED distribution was also evaluated with radiobiological parameters derived from literature (α/β=10, μ repair =0.5 h -1 ). Dose-volume and BED-volume histograms were generated, and the corresponding average BED (BED voxel ) obtained. EUD was estimated considering the surviving fraction of the target (α=0.3 Gy -1 ). Results:

Absorbed doses (average±SD) from standard vs. voxel dosimetry were (19.5±4.0) vs (22.2±3.0) Gy (difference: 12±3%). As regards the mean BED values: (21.2±4.3) vs. (24.4±3.2) Gy. The BEDvolume histograms showed that 68±25% of voxels received a BED>21 Gy. All voxels received a BED>14 Gy. The EUD/BED voxel ratio was 0.9, indicative of slight heterogeneous dose distribution. Conclusions: Radiobiological evaluations indicated that IART ® allows delivering tumoural bed an anticipated boost comparable to a EBRT boost. The absorbed doses evaluated with standard method were systematically lower than those calculated with voxel method (differences up to 16%). The EUD/BED voxel ratio in the target indicated biological efficacy comparable or close to that of uniform dose distribution, thus the hypothesis of uniform activity distribution is not misleading. The voxel method is recommended for improving accuracy on activity distribution in the breast tissue.

Tumor Dosimetry In The Treatment Of Liver Metastases With SIRTEX Does Not Correlate With Therapeutic Response L. Aloj 1 , C. Arrichiello 1 , F. Izzo 2 , R. D'Angelo 3 , F. Fiore 3 , S. Lastoria 1 ; 1 Nuclear Medicine, Istituto Nazionale Tumori, Fondazione "G. Pascale", Napoli, ITALY, 2 Surgical Oncology, Istituto Nazionale Tumori, Fondazione "G. Pascale", Napoli, ITALY, 3 Interventional Radiology, Istituto Nazionale Tumori, Fondazione "G. Pascale", Napoli, ITALY.

Use of 90Y-microspheres for Selective Internal Radiotherapy (SIR) of primary or metastatic liver cancer is increasing. Treatment with SIR-microspheres is based on the notion that arterial blood supply in tumor metastases is higher than portal hepatic flow, therefore microspheres delivered by hepatic artery will be deposited at higher concentration in tumor areas, decaying by beta emission. The heterogeneity of liver activity distribution observed in the pre-treatment breakthrough scan with 99mTc-MAA appear to confirm this hypothesis. Although tumor doses estimated with the MIRD approach from pre-treatment static images are considerably high (~100Gy), we observed a great variability in treatment responses. The correlation between areas of increased microsphere concentration in SPECT images and tumor active areas visible on PET images, was investigated. In detail, we evaluated the relationship between response, based on average SUV variations of lesions between pre-and post-therapy PET studies, and TLR (tumor to liver ratio) of the same lesions in SPECT images. Eight patients with 31 liver metastases from different primary tumors (breast, melanoma, colo-rectal cancer) were analyzed. Each patient underwent static (256x256 pixels, 140 keV±15% peak) and SPECT (128x128, 64 views) scans, after 99mTc-MAA injection (185 MBq) 1-3 weeks prior to treatment. 18F-FDG wholebody PET was performed before and 6-8 weeks after 90Y-SIRspheres therapy. Injected activity was defined using the Body Surface Area Method and MIRD equations were utilized to measure lung and normal (un-involved) liver absorbed doses, which should be below 20 Gy and 80 Gy respectively. Applying the MIRD equations we estimated the mean dose delivered to normal liver was: 30±7 Gy (20±6 Gy/GBq) while for lungs: 3.6±3Gy (2.1±1.7Gy/GBq). The wide range in lung is caused by highly variable shunting fractions among patients. On the basis of our experience no patients exceeded dose limits in organs at risk. PET images before and after treatment were registered and compared to define SUV variations for all lesions. The same areas were selected on SPECT images to determine TLR. Regions showing uptake in SPECT colocalized with uptake areas observed in pre-treatment PET. Lesion absorbed doses based on the results obtained in pretreatment simulation do not correlate with the degree of response, suggesting that treatment efficacy is highly dependent on individual biological features of the tumor deposits.

the PFC, supporting the hypothesis that the ACC and thalamus play a role in learning and reward anticipation

4 ; 1 Asan Medical Center

Both blinded visual interpretation and region of interest (ROI) analysis using striatal specific to occipital uptake ratio (SOR) were performed on static PET/CT images obtained at 90 min after the injection of 185 MBq of F-18 FP-CIT. Acute adverse reaction of F-18 FP-CIT injection was also evaluated. All of 39 PD and one of ET showed asymmetrical reduction of striatal uptake on visual analysis. Therefore, visual interpretation demonstrated a sensitivity of 100% and specificity of 97% comparing PD versus controls (ET+HV)

OP504 Amyotrophic lateral sclerosis: a [ 123 I]FP-CIT SPECT study N. Pisciotta 1 , A. Niccoli Asabella 1 , I. Montemurro 1 , M. L. Altieri

The regions of interest (the whole brain, the thalamus, brainstem, the anterior cingulate cortex, the temporal cortex, and the caudate) were delineated on the coregistered MRI/PET images. The regional brain uptakes and BP ND values from reference tissue models (simplified reference tissue model and multilinear reference tissue model) with different time lengths were compared

-D 2 (5.3 %) than for

4%) while the washout after the peak were slower for

64% of the peak uptake at 120 min) than for

-D 2 (approximately 50% of the peak uptake at 120 min). The regional uptakes in the thalamus and the brainstem with [ 11 C]MeNER did not always reach the peak during 123-min measurements

-D 2 did reach the peak before 30 min. The specific binding (regional uptake-the caudate) for (S,S)

MeNER did not reach the peak during 123 min measurements whereas

-D 2 did reach the peak before 80 min except for the temporal cortex. The ratios of the region to the caudate

-D 2 reached the plateau

were not stable during 123 min measurement. The outcome measures of

were not obviously improved with higher radioactivity. Conclusions: (S,S)

FMeNER-D 2 was demonstrated to be superior for the quantitative analysis with reference

Catafau 7 ; 1 Neurosciences Imaging Group

Emission scans included 9 passes acquired up to 2h. Regions of interest were drawn on 3D PET images on subsamples of the organs, when needed the CT image was used to identify organs. The regions of interest were drawn on the kidneys, liver, urinary bladder, lungs, heart, gallbladder, brain, stomach, large intestine (ascending colon), small intestine (duodenum), cortical bone (skull and femur) and red marrow (femur). Residence times for each organ were calculated from the area under the time-activity curves divided by injected activity. Area under the time-activity curve for each region was determined by trapezoidal integration plus physical decay for the tail of the curve after the last acquired time point

Progressive increase in the activity of the stomach and small intestine was also observed. The principal route of clearance was intestinal and no urinary excretion was observed. The limiting organ with the highest radiation-absorbed dose was the liver (9.96±0.02 μSv/MBq) and the mean effective dose was 3.79±0.34 μSv/MBq Conclusion: The liver is the critical organ for 11 C-GSK931145 in humans. Derivation of total and organ radiation burden of 11 Cthis ligands, for studies such as occupancy studies supporting the development of GlyT inhibitors candidate drugs

A new pet ligand for glycine transporter 1

The second-generation personal computer software for internal dose assessment in nuclear medicine

Aim: Standardised reporting criteria are required in multicentre trials to ensure consistency in image interpretation. The aim of this study was to determine if reporting criteria developed for the Response Adapted Treatment in Hodgkin Lymphoma (RATHL) trial were sufficiently robust to enable satisfactory agreement to be reached between centres acting as 'core labs' reporting scans in different countries. Methods: Four European centres viewed the same 100 FDG PET scans from 50 patients with HL, acquired before chemotherapy and after 2 cycles of ABVD. Datasets were anonymised and saved in DICOM format. Each centre used their standard reporting software. A five point scale was used to score uptake in regions involved by lymphoma at staging : 1) no increased uptake 2) uptake less than or equal to mediastinum 3) uptake greater than mediastinum but less than or equal to liver 4) moderately increased uptake compared to liver 5) markedly increased uptake compared to liver. Centres read scans independently then discussed scans where there was disagreement to determine if consensus could be reached. For the RATHL study a score of 1, 2 or 3 is regarded as 'negative' and a score of 4 or 5 is regarded as 'positive' for lymphoma. A positive scan results in escalation of chemotherapy to BEACOPP or escalated BEACOPP. Results: There was agreement that the response scan was 'positive' or 'negative' for lymphoma in 44/50 patients when scans were read independently at four centres. Consensus was reached in 46/50 patients after discussion. Kappa for negative (score 1,2,3) vs positive (score 4,5) was 0.85 (95% CI 0.74-0.96) for the independent read (very good agreement) and 0.90 (95% CI 0.79 -1.00) for the consensus read (very good agreement). The data were reanalyzed, considering score 3 as a separate category that was 'equivocal' for disease. There was agreement in 40/50 scans on independent reading and 44/50 scans with consensus reading. Kappa for negative (score 1,2) vs equivocal (score3) vs positive (score 4,5) was 0.76 (95%CI 0.66-0.85) (good agreement) and 0.85 (95%CI 0.75-0.95) (very good agreement) for independent and consensus reading respectively. Conclusion: The criteria developed for interpretation of PET scans in the RATHL study are sufficiently robust to be used in a multicentre setting. Continued audit will be required to ensure consistency in reporting is maintained. The criteria could be adapted to change the threshold for 'positivity' according to the clinical or research context.

Interim PET in Hodgkin lymphoma: comparison of the different criteria to evaluate chemotherapy response A. Biggi, S. Chauvie, A. Bianchi, F. Fiore, A. Gallamini; S Croce and Carle Hospital, Cuneo, ITALY.Aim: Interim FDG-PET (iPET) is strongly correlated with progression-free survival in Hodgkin lymphoma (HD). However the criteria to define negative or positive iPET are not yet clearly defined. In this study we compared the accuracy of different qualitative methods to evaluate therapy response with iPET. Moreover, we explored the incremental prognostic power of a semiquantitative analysis using SUVmax. Material and methods: We retrospectively analyzed 58 HD patients with a baseline and iPET performed after two cycle of ABVD treatment. Images were evaluated visually comparing the uptake in the residual to a reference using the following criteria: iPET positive if: 1) uptake > liver; 2) uptake > liver and dimension >= 2 cm or uptake = liver and dimension < 2 cm; 3) uptake > mediastinal blood pool structure (MBPS); 4) uptake > MBPS and dimension >= 2 cm or uptake = MBPS and dimension < 2 cm.. The 4 criteria were then revised in patients with uptake between MBPS and liver; iPET was set positive if SUVmax was > than threshold. Results of iPET were compared with the clinical status at follow-up (range 138-1783 days). Results: during post-treatment follow-up 6 pts had a progression disease (3 died) and 52 were in complete regression. A cut-off value of 3.5, determined using ROC analysis, was utilized to distinguish negative from positive results in iPET. In the table are reported the results obtained using the four criteria of interpretation. In bold are evidenced the results obtained using SUVmax as an additional parameter.Method: TP (withSUV) FP (withSUV) FN (withSUV) TN(withSUV) Accuracy(withSUV) The number of TP and FN patients is the same using the different criteria except for criteria 1) that has a relative lower TP rate and higher FN rate while the different criteria significantly affects the FP rate. A SUVmax.>3.5 applied to a qualitative interpretation of iPET increases the accuracy and reduces the FP rate the best results being observed using criteria 1. Conclusions: in iPET the number of FP results is influenced by the criteria utilized for defining a study positive or negative. The number of FP is higher using MBPS as a reference than liver. The dimension criteria linked to a qualitative scoring system increase the number of FP. The SUVmax linked to a qualitative analysis increases always the accuracy.Aim: Reward capacity, or the ability to respond to positive reinforcers, is an important feature of human behaviour and protects an individual against different psychiatric illnesses. Mesocorticolimbic dopamine (DA) neurotransmission, particularly in the extrastriatal part of the reward circuit, plays a role in the ability to experience pleasure (liking the reward), but also in behaviours like motivation and drive (wanting the reward and learning). , reflecting specific D 2 /D 3 binding changes, were computed to localize areas with increased ligand displacement after the task initiation hence DA release. These t-maps were correlated with behavioural measures for reward responsiveness and feedback-related behaviour to probabilistic reward (learning and reward anticipation) (SPM2; p height <0.001). Results: Voxel-based analysis revealed a significant inverse correlation between reward capacity and DA release in the ventral medial PFC (Brodmann Area (BA) 10), orbitofrontal PFC (BA 11) and ACC (BA 32). Furthermore, the ACC and thalamic DA displacement shows a significant positive correlation with feedback-related negativity to probabilistic rewards. Conclusion: These findings support the hypothesis that several extrastriatal brain areas are involved in reward capacity. Individuals with lower reward responsiveness show a higher DA release in prefrontal areas and the ACC during a reward challenge. This is consistent with previous literature and implicates greater attendance to the reward context of potential rewarding stimuli in less reward sensitive individuals. Furthermore, integration of reinforcement history over time inversely correlates with thalamic and ACC DA release, but not with DA release Aim: The competitive binding of benzamide radioligands at dopamine D2-receptors has been employed to great effect for molecular imaging studies of dopamine release in living human brain. However, PET ligands labelled with C-11 are only available at sites with cyclotronradiochemistry facilities, whereas SPECT suffers from limited spatial resolution. Therefore, we tested the fitness of the high affinity ligand [18F] fallypride (FP) and its lower affinity congener [18F] desmethoxyfallypride (DMFP) for revealing endogenous competition in mouse brain. The small size of mouse striatum relative to the resolution of microPET results in substantial vulnerability to bias. Therefore, accuracy of the microPET methods was assessed in comparison with "gold-standard" results obtained by brain dissection. Materials and Methods: Groups of awake mice were pretreated with saline, amphetamine (10 mg/kg) or reserpine (5 mg/kg), followed by i.v. tracer injections. Mice were killed at 2.5 to 90 min (DMFP) or 2.5 to 210 min (FP). Brains were dissected and radioactivity measured by gamma counting. Constructed timeradioactivity curves were used to calculate binding potentials (BPND) using cerebellum as reference region. Other groups of mice were anesthetized for FP or DMFP microPET recordings, in which four mice were scanned simultaneously. Maps of BPND were calculated by conventional methods and transformed into a standard coordinate system for mouse brain. Results: The DMFP BPND in striatum was 2.2 according to the gold standard method, and 2.1 according to microPET. In contrast, the FP BPND in striatum was 24 according to the gold standard method and only 9 by microPET; the bias seemed to arise from progressive spill-in of bone radioactivity to the cerebellum. DMFP proved to be highly vulnerable to amphetamine challenge, declining by as much as 60% in the microPET studies, and increasing by 30% after reserpine treatment. FP binding in striatum was likewise vulnerable to amphetamine treatment (-30%). Reserpine treatment did not increase FP binding in striatum, but nearly doubled the binding in the olfactory bulbs, as revealed by the gold standard dissection method. Conclusions: FP microPET results were biased due to spill-over from striatum and spill-in of bone signal to cerebellum. In contrast, DMFP microPET results were seemingly unbiased. Striatal binding of both ligands was highly vulnerable to altered competition from endogenous dopamine; we detected an unexpectedly high basal occupancy by dopamine at receptors in the olfactory bulb. The [18F] -labelled benzamides should make the amphetamine challenge paradigm accessible to PET centres lacking a cyclotron unit. (SPM5) was then used to localize striatal binding in ALS and to compute the absolute change relative to 5 age-matched healty control (H) and 5 age-matched PD pts. Results. In ALS pts the overall uptake in basal ganglia was significantly greater than H group (P < 0.01) and PD groups (P < 0.0001). SPM5 comparison of 123 I-FP-CIT uptake in the ALS and control groups revealed the presence of a significant increase in both putamen and caudate (P < 0.01; two-tailed Student's ttest). Similar findings were obtained considering separately right and left caudate and putamen. Conclusions. Our results confirm data of some studies in which functional MRI has revealed the hyperfunction of cortical and subcortical extramotor systems (basal ganglia and cerebellum) in patients with ALS, probable expression of a compensatory mechanism due to phenomena of neuronal plasticity and functional reorganization in motors and sensors circuits controlling the movement. A confirmation of this hyperfunction, a preliminary data on an assessment of the ways of pain in patients with ALS, have suggested the hypothesis of central pain with a likely "compensatory hyperactivity of cortical sensory areas. The aim of this study was therefore to evaluate whether [ 123 I]ADAM binds selectively in humans.

Using a double-blind study design, 12 healthy young male adults (age 18-30 years) were pre-treated orally with a selective serotonin transporter blocker (20 mg of the selective serotonin reuptake inhibitor paroxetine), a dopamine/norepinephrine transporter blocker (20 mg of the dopamine/norepinephrine reuptake inhibitor methylphenidate) or placebo. Then each subject was injected intravenously with a bolus of 140-180 MBq ADAM (produced by Schering, Finland; radiochemical purity > 95%). SPECT images were acquired 5 hrs p.i. using a brain-dedicated SPECT system (Neurofocus; a 12-detector single slice scanner). All images were corrected for attenuation and reconstructed in 3D mode. For analysis purposes, the SPECT images were co-registrated with individual MRI scans (obtained on a 3T machine). ROIs were drawn manually on the co-registrated MRI scans in SERT-rich brain areas (midbrain), and ADAM binding in the cerebellar cortex was used to assess non-specific binding. Specific to non-specific binding ratios were calculated and used as the outcome measure. Results: Binding ratios were statistically significantly lower in the paroxetine pre-treated group as compared to the placebo as well as to the methylphenidate pre-treated group (non-parametric tests). Binding ratios in the methylphenidate pre-treated group were not significantly different from such ratios obtained in the placebo pre-treated group. introduced within the 11C methyl group together with the introduction of deuterium. Although these two NET radioligands have been reported to have different characteristics, there has not been a direct comparative study in vivo. In this study, we compared the brain distribution and outcome measures from reference tissue models in the same rhesus monkeys of these two NET radioligands. Methods: Two rhesus monkeys underwent three PET measurements each, one with (S,S)-[ 18 F]FMeNER-D 2 (156MBq) and two with different amounts of radioactivity of (S,S)- Objectives: The aim of the study was to investigate the DNA damage response in blood lymphocytes as measured by the induction, persistence and the decay behaviour of γ-H2AX and 53BP1 DNA damage-induced foci in patients with differentiated thyroid carcinoma (DTC) treated with I-131. γ-H2AX forms foci surrounding radiation-induced double strand breaks (DSBs) while 53BP1 binds to and signals damaged chromatin (histone H3-K79) at the DSB site and is thereafter retained by γ-H2AX. Nuclear foci containing the two markers thus represent DSBs. Methods: We investigated 25 patients (7m, 18f, age 42±13) diagnosed with DTC during their first treatment with I-131. Sequential peripheral blood samples and data on the external dose rate were obtained between 2h and 144h after the administration of 3.5±0.6 GBq I-131. The physical dosimetry procedures were performed according to the EANM SOPs for pre-therapeutic dosimetry in DTC therapy (1). The average frequencies of the radiation induced γ-H2AX and 53BP1 foci/nucleus were derived from mononuclear peripheral blood lymphocyte samples taken prior to therapy and concurrently to dosimetric blood sampling. White blood cells were recovered by CPT (BD Biosciences) column centrifugation and immunostained as described in (2) Objectives: 13-cis retinoic acid was demonstrated in past studies to be able to re-differentiate thyroid carcinoma (TC) that had lost their ability to take up iodine. However, these observations were obtained after the systematic administration of Iodine-131 therapeutic activities (TA) in all patients. Our aim was to evaluate PET-CT imagings with Iodine-124 as a way to define the responders to such re-differentiation therapy (RDT). Material and methods: 2 men and 2 women with metastatic TC who showed on previous 131-I treatments very faint (even no) or decreasing iodine uptake (IUpt) in their lesions have been up to now enrolled in this phase II clinical trial. Using a dedicated full-ring PET/CT scanner (GE medical systems, Discovery LS), PET-CT imagings were obtained under Thyrogen stimulation 24, 48 and 120 hours after the IV injection of 1 mCi of Iodine-124, before and after 8 to 10 weeks of daily intake of 1 mg/kg of 13-cis retinoic acid. Standard clinical software available on the Advance scanner has been used. 3D raw data were rearranged in a 2D-raw data sinogram by Fourier rebinning. All scans were normalized and corrected for randoms, scatter, attenuation, and decay. The images (matrix 128x128) were reconstructed using attenuation and normalization weighted OSEM algorithm followed by postsmoothing of the reconstructed image using a 8-mm FWHM Gaussian filter. Reconstructions without attenuation correction were done as well. Results: One first (male) patient with no uptake in his lesions showed no further uptake after RDT (he was not treated and died 4 months later). The second (female) patient had very faint uptake in her lesions before treatment and the mean IUpt was increased by a factor 3 after treatment. The third (female) patient with no IUpt showed no change after 2 months of RDT but well in a single pulmonary metastases after 5 months. The fourth (male) patient also showed a three-fold increase of IUpt in some lesions. In these patients with multiple lesions, change in IUpt appeared to be heterogeneous. The last 3 patients received thereafter TA (7400 MBq) of 131-Iodine (the last patient the 13/03/2009). The second patient showed a radiolysis due to 131-I treatment and a transient biological response lasting two months before re-evolution. The third patient is stable 4 months after treatment. Conclusion: PET-CT imaging with iodine-124 can show subtle changes IUpt after RDT and be used to select the patients to be treated with iodine-131. Aim: The goal of this work was to study the S-Voxel method on 90Y Bremsstrahlung and 111In imaging to assess a dosimetric model suitable for therapeutic applications.

An anthropomorphic thorso phantom, with radioactive inserts of different dimensions, was used to obtain the activity quantification by SPECT-CT imaging. The acquisitions were achieved by a hybrid system and parameters set as follows: energy windows between 36 and 204 keV for 90Y, at 247 (±15%) and 172 keV (±15%) for 111In (with three scatter windows); medium energy collimators; acquisition matrix 128x128; 64 projections (40s/step). A concomitant low-dose CT was obtained for attenuation correction and the OSEM 3D-Fast algorithm was used for the reconstruction of images. An algorithm for MATLAB ® software was developed to convert a 3Dvoxel cumulated activity map into the correspondent dose distribution while considering the 90Y-S values implemented. The dose volume histograms (DVHs) calculated by the above described method were then compared with the ones obtained by calculation of the local energy absorption. Results: A large variability of calibration factors (CFs) for 90Y was observed for source volumes ranging from 8 to 150 cc, due to the partial volume effect. A minor variability of CFs was reported by employing 111In sources. The full width at half maximum (FWHM), in air by a static acquisition and in a plexiglas phantom by tomographic acquisition resulted 19 mm and 30 mm for the 90Y and 14 mm and 19 mm for 111In. The thresholds for source identification (in absence of background activity) were ranging from 35 to 55% for 90Y and from 20 to 35% for 111In. By introducing the CFs, the 90Y-and 111In-related overall variation for clinical application was within 20%. The DVHs obtained by S-Voxel method were consistent with the DVHs resulted from the local absorption of energy. Moreover, for 90Y we tested the coherence between the absorbed dose calculated in the phantoms by conventional MIRD method and the mean dose values obtained by the S-Voxel method (difference< 10%).Conclusions: The results of the studies showed a good accuracy of 3-D quantification for 90Y and 111In and a coherence between the S-Voxel and MIRD methods. Anyhow, the S-Voxel method, represents, in our opinion, a more accurate dosimetric procedure (in terms of equivalent uniform dose EUD) to take into account for a tailored radiotargeted therapy. In-DOTA-KAA-BN, with a 5-fold lower uptake in the receptor-positive organs pancreas and colon, and reduced kidney uptake (3.9 vs. 5.0 %ID/g, 1 h p.i.). Tumor uptake was similar for both analogues but 111 In-DOTA-PEG-KAA-BN showed improved SPECT/CT imaging. Conclusion: PEGylation of BN analogues resulted in favorable biodistribution, which led to higher signal-to-noise ratios and improved in vivo imaging. The PEGylated analogues showed preferential renal clearance and lower accumulation in the gastrointestinal tract. This would translate into lower whole-body radiation exposure and be advantageous to increase their therapeutic potential. localized in the tumor (5.7 ± 1.6 %ID/g at 4 h pi and 2.7 ± 0.5 %ID/g at 24 h pi) and in the stomach (3.6 ± 0.5 %ID/g at 4 h pi and 2.3 ± 0.2 %ID/g at 24 h pi). Uptake in the blocked animal group was significantly reduced (0.3%ID/g and 0.1%ID/g, respectively, at 4 h pi) implying a CCK-2-R mediated process. Kidney uptake was significant at 4 h pi (>100%ID/g) and remained at high levels even at 24 h pi (75%ID/g). Conclusions: This work has shown that Gastrin I-based radioligands can target CCK2-R-positive tissues in vivo equally well or better than their minigastrin-based counterparts. Although the observed high kidney uptake and retention may represent a species-related finding not reproduced in human, work is currently in progress to reduce renal values by kidney protection regimens (e.g. administration of poly-glutamates, gelofusine, or other agents and combinations thereof). showed undesirable high uptake in the kidneys (7.85±1.94%ID/g) being much less for the other analogues. AMBA, MP2346 and Pesin revealed favourable increases in tumour to blood ratios over time while changes in tumour-to kidney and pancreas ratios for DB1 1 to 24h after injection were significantly better than for the other analogues (see table I ). All analogues visualised PC tumours by SPECT-CT and autoradiography. HPLC analysis showed intact DB1 at 5 and 15min after injection (64.1%±1.6 and 41.0%±01, respectively) being much less for the other compounds. AMBA, the second most stable analogue, showed 36.1%±2.7 and 9.8%±1.1 intact peptide after 5 and 15min. Conclusion GRPR expression was high, but variable, in the majority of PC samples with no clear distinction between various stages. In our study DB1 was the best performing analogue showing best in vivo stability, high tumour-uptake and retention while pancreatic clearance was rapid. Pesin and AMBA were the best GRP-agonists with high tumour-uptake and retention. DB1 has been selected for use in a phase I trial. Pharmacologically, being an antagonist, this analogue is expected to cause few side effects. Initially, 10 patients with histologically proven PC will be included for DB1-SPECT prior to scheduled radical prostatectomy to evaluate accuracy of PC detection. SPECT images will be verified using histopathology as the "golden standard". Tb-DOTA-chCE7 bind to L1-CAM expressing tumor cells and internalize rapidly. The radioimmunoconjugates have excellent targeting properties in vivo with high accumulation at the tumor site and low activity in nontargeted organs. First results on the comparative therapeutic efficacy will be presented.